Glue for cartilage repair

The invention is directed toward a sterile cartilage defect implant material comprising milled lyophilized allograft cartilage pieces ranging from 0.01 mm to 1.0 mm in size in a bioabsorbable carrier taken from a group consisting of sodium hyaluronate, hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran or polymers with allogenic chondrocytes or bone marrow cells in an amount exceeding the natural occurrence of same in hyaline cartilage and adding a cell growth additive.

Skip to: Description  ·  Claims  ·  References Cited  · Patent History  ·  Patent History
Description
RELATED APPLICATIONS

There is no related application. The instant application is a reissue of application Ser. No. 10/424,765, filed Apr. 29, 2003, and issued as U.S. Pat. No. 7,067,123.

1. Field of Invention

The present invention is generally directed toward an implant and is more specifically directed toward a paste or gel implant material for a cartilage defect.

2. Background of the Invention

Articular cartilage injury and degeneration present medical problems to the general population which are addressed by orthopedic surgeons. Every year in the United States, over 500,000 arthroplastic or joint repair procedures are performed. These include approximately 125,000 total hip and 150,000 total knee arthroplasties and over 41,000 open arthroscopic procedures to repair cartilaginous defects of the knee.

In the knee joint, the articular cartilage tissue forms a lining which faces the joint cavity on one side and is linked to the subchondral bone plate by a narrow layer of calcified cartilage tissue on the other. Articular cartilage (hyaline cartilage) consists primarily of extracellular matrix with a sparse population of chondrocytes distributed throughout the tissue. Articular cartilage is composed of chondrocytes, type II collagen fibril network, proteoglycans and water. Active chondrocytes are unique in that they have a relatively low turnover rate and are sparsely distributed within the surrounding matrix. The collagens give the tissue its form and tensile strength and the interaction of proteoglycans with water give the tissue its stiffniess to compression, resilience and durability. The hyaline cartilage provides a low friction bearing surface over the bony parts of the joint. If the lining becomes worn or damaged resulting in lesions, joint movement may be painful or severely restricted. Whereas damaged bone typically can regenerate successfully, hyaline cartilage regeneration is quite limited because of it's limited regenerative and reparative abilities.

Articular cartilage lesions generally do not heal, or heal only partially under certain biological conditions due to the lack of nerves, blood vessels and a lymphatic system. The limited reparative capabilities of hyaline cartilage usually results in the generation of repair tissue that lacks the structure and biomechanical properties of normal cartilage. Generally, the healing of the defect results in a fibrocartilaginous repair tissue that lacks the structure and biomedical properties of hyaline cartilage and degrades over the course of time. Articular cartilage lesions are frequently associated with disability and with symptoms such as joint pain, locking phenomena and reduced or disturbed function. These lesions are difficult to treat because of the distinctive structure and function of hyaline cartilage. Such lesions are believed to progress to severe forms of osteoarthritis. Osteoarthritis is the leading cause of disability and impairment in middle-aged and older individuals, entailing significant economic, social and psychological costs. Each year, osteoarthritis accounts for as many as 39 million physician visits and more than 500,000 hospitalizations. By the year 2020, arthritis is expected to affect almost 60 million persons in the United States and to limit the activity of 11.6 million persons.

There are many current therapeutic methods being used. None of these therapies has resulted in the successful regeneration of hyaline-like tissue that withstands normal joint loading and activity over prolonged periods. Currently, the techniques most widely utilized clinically for cartilage defects and degeneration are not articular cartilage substitution procedures, but rather lavage, arthroscopic debridement, and repair stimulation. The direct transplantation of cells or tissue into a defect and the replacement of the defect with biologic or synthetic substitutions presently accounts for only a small percentage of surgical interventions. The optimum surgical goal is to replace the defects with cartilage-like substitutes so as to provide pain relief, reduce effusions and inflammation, restore function, reduce disability and postpone or alleviate the need for prosthetic replacement.

Lavage and arthroscopic debridement involve irrigation of the joint with solutions of sodium chloride, Ringer or Ringer and lactate. The temporary pain relief is believed to result from removing degenerative cartilage debris, proteolytic enzymes and inflammatory mediators. These techniques provide temporary pain relief, but have little or no potential for further healing.

Repair stimulation is conducted by means of drilling, abrasion arthroplasty or microfracture. Penetration into the subchondral bone induces bleeding and fibrin clot formation which promotes initial repair, however, the tissue formed is fibrous in nature and not durable. Pain relief is temporary as the tissue exhibits degeneration, loss of resilience, stiffness and wear characteristics over time.

The periosteum and perichondrium have been shown to contain mesenchymal progenitor cells capable of differentiation and proliferation. They have been used as grafts in both animal and human models to repair articular defects. Few patients over 40 years of age have obtained good clinical results, which most likely reflects the decreasing population of osteochondral progenitor cells with increasing age. There have also been problems with adhesion and stability of the grafts, which result in their displacement or loss from the repair site.

Transplantation of cells grown in culture provides another method of introducing a new cell population into chondral and osteochondral defects. Carticel® is a commercial process to culture a patient's own cartilage cells for use in the repair of cartilage defects in the femoral condyle marketed by Genzyme Biosurgery in the United States and Europe. The procedure uses arthroscopy to take a biopsy from a healthy, less loaded area of articular cartilage. Enzymatic digestion of the harvested tissue releases the cells that are sent to a laboratory where they are grown for a period ranging from 2-5 weeks. Once cultivated, the cells are injected during a more open and extensive knee procedure into areas of defective cartilage where it is hoped that they will facilitate the repair of damaged tissue. An autologous periosteal flap with cambium layer is used to seal the transplanted cells in place and act as a mechanical barrier. Fibrin glue is used to seal the edges of the flap. This technique preserves the subchondral bone plate and has reported a high success rate. Proponents of this procedure report that it produces satisfactory results, including the ability to return to demanding physical activities, in more than 90% of patients and that biopsy specimens of the tissue in the graft sites show hyaline-like cartilage repair. More work is needed to assess the function and durability of the new tissue and determine whether it improves joint function and delays or prevents joint degeneration. As with the perichondrial graft, patient/donor age may compromise the success of this procedure as chondrocyte population decreases with increasing age. Disadvantages to this procedure include the need for two separate surgical procedures, potential damage to surrounding cartilage when the periosteal patch is sutured in place, the requirement of demanding microsurgical techniques, and the expensive cost of the procedure which is currently not covered by insurance.

Osteochondral transplantation or mosaicplasty involves excising all injured or unstable tissue from the articular defect and creating cylindrical holes in the base of the defect and underlying bone. These holes are filled with autologous cylindrical plugs of healthy cartilage and bone in a mosaic fashion. The osteochondral plugs are harvested from a lower weight-bearing area of lesser importance in the same joint. This technique, shown in Prior Art FIG. 2, can be performed as arthroscopic or open procedures. Reports of results of osteochondral plug autografts in a small number of patients indicate that they decrease pain and improve joint function, however, long-term results have not been reported. Factors that can compromise the results include donor site morbidity, effects of joint incongruity on the opposing surface of the donor site, damage to the chondrocytes at the articular margins of the donor and recipient sites during preparation and implantation, and collapse or settling of the graft over time. The limited availability of sites for harvest of osteochondral autografts restricts the use of this approach to treatment of relatively small articular defects and the healing of the chondral portion of the autograft to the adjacent articular cartilage remains a concern.

Transplantation of large allografts of bone and overlying articular cartilage is another treatment option that involves a greater area than is suitable for autologous cylindrical plugs, as well as for a non-contained defect. The advantages of osteochondral allografts are the potential to restore the anatomic contour of the joint, lack of morbidity related to graft harvesting, greater availability than autografts and the ability to prepare allografts in any size to reconstruct large defects. Clinical experience with fresh and frozen osteochondral allografts shows that these grafts can decrease joint pain, and that the osseous portion of an allograft can heal to the host bone and the chondral portion can function as an articular surface. Drawbacks associated with this methodology in the clinical situation include the scarcity of fresh donor material and problems connected with the handling and storage of frozen tissue. Fresh allografts carry the risk of immune response or disease transmission. Musculoskeletal Transplant Foundation (MTF) has preserved fresh allografts in a media that maintains a cell viability of 50% for 35 days for use as implants. Frozen allografts lack cell viability and have shown a decreased amount of proteoglycan content which contribute to deterioration of the tissue.

A number of patents in the prior art show the use of bone putty, pastes or gels to fill bone defects. U.S. Pat. No. 5,290,558 issued Mar. 1, 1994 discloses a flowable demineralized bone powder composition using an osteogenic bone powder with large particle size ranging from about 0.1 to about 1.2 cm. mixed with a low molecular weight polyhydroxy compound possessing from 2 to about 18 carbons including a number of classes of different compounds such as monosaccharides, disaccharides, water dispersible oligosaccharides and polysaccharides.

A bone gel is disclosed in the U.S. Pat. No. 5,073,373 issued Dec. 17, 1991. Bone lamellae in the shape of threads or filaments retaining low molecular weight glycerol carrier are disclosed in U.S. Pat. Nos. 5,314,476 issued May 24, 1994 and 5,507,813 issued Apr. 16, 1996 and the tissue forms described in these patents are known commercially as the GRAFTON® Putty and Flex, respectively.

U.S. Pat. No. 5,356,629 issued Oct. 18, 1994 discloses making a rigid gel in the nature of a bone cement to fill defects in bone by mixing biocompatible particles, preferably polymethylmethacrylate coated with polyhydroxyethylmethacrylate in a matrix selected from a group which lists hyaluronic acid to obtain a molded semi-solid mass which can be suitably worked for implantation into bone. The hyaluronic acid can also be utilized in monomelic form or in polymeric form preferably having a molecular weight not greater than about one million Daltons. It is noted that the nonbioabsorbable material which can be used to form the biocompatible particles can be derived from xenograft bone, homologous bone, autogenous bone as well as other materials. The bioactive substance can also be an osteogenic agent such as demineralized bone powder, morselized cancellous bone, aspirated bone marrow and other autogenous bone sources. The average size of the particles employed is preferably about 0.1 to about 3.0 mm, more preferably about 0.2 to about 1.5 mm, and most preferably about 0.3 to about 1.0 mm. It is inferentially mentioned but not taught that particles having average sizes of about 7,000 to 8,000 microns, or even as small as about 100 to 700 microns can be used.

U.S. Pat. No. 4,172,128 issued Oct. 23, 1979 discloses a demineralized bone material mixed with a carrier to reconstruct tooth or bone material by adding a mucopolysaccharide to a mineralized bone colloidal material. The composition is formed from a demineralized coarsely ground bone material, which may be derived from human bones and teeth, dissolved in a solvent forming a colloidal solution to which is added a physiologically inert polyhydroxy compound such as mucopolysaccharide or polyuronic acid in an amount which causes orientation when hydrogen ions or polyvalent metal ions are added to form a gel. The gel will be flowable at elevated temperatures above 35° C. and will solidify when brought down to body temperature. Example 25 of the patent notes that mucopolysaccharides produce pronounced ionotropic effects and that hyaluronic acid is particularly responsible for spatial cross-linking.

U.S. Pat. No. 6,030,635 issued Feb. 29, 2000 and U.S. Pat. No. 6,437,018 issued Aug. 20, 2002 are directed toward a malleable bone putty and a flowable gel composition for application to a bone defect site to promote new bone growth at the site which utilize a new bone growth inducing compound of demineralized lyophilized allograft bone powder. The bone powder has a particle size ranging from about 100 to about 850 microns and is mixed in a high molecular weight hydrogel carrier which contains a sodium phosphate saline buffer.

The use of implants for cartilage defects is much more limited. Aside from the fresh allograft implants and autologous implants, U.S. Pat. No. 6,110,209 issued Nov. 5, 1998 shows the use an autologous articular cartilage cancerous bone paste to fill arthritic defects. The surgical technique is arthroscopic and includes debriding (shaving away loose or fragmented articular cartilage), followed by morselizing the base of the arthritic defect with an awl until bleeding occurs. An osteochondral graft is then harvested from the inner rim of the intercondylar notch using a trephine. The graft is then morselized in a bone graft crusher, mixing the articular cartilage with the cancellous bone. The paste is then pushed into the defect and secured by the adhesive properties of the bleeding bone. The paste can also be mixed with a cartilage stimulating factor, a plurality of cells, or a biological glue. All patients are kept non-weight bearing for four weeks and used a continuous passive motion machine for six hours each night. Histologic appearance of the biopsies have mainly shown a mixture of fibrocartilage with hyaline cartilage. Concerns associated with this method are harvest site morbidity and availability, similar to the mosaicplasty method. cl SUMMARY OF THE INVENTION

A cartilage implant material in paste or gel form for repairing articular cartilage defects is composed of milled allograft cartilage pieces in a bioabsorbable carrier. Autologous chondrocyte in an amount exceeding the number naturally occurring in hyaline cartilage for a mature adult between 20 and 55 years of age may also be applied to the matrix. Additives may be applied to the mixture in order to increase chondrocyte migration and proliferation. The implant material can support the addition of a variety of chondrogenic stimulating factors including, but not limited to growth factors (FGF-2, FGF-5, IGF-1, TGF-β, BMP-2, BMP-7, PDGF, VEGF), human allogenic or autologous chondrocytes, human allogenic or autologous bone marrow cells, stem cells, demineralized bone matrix, insulin, insulin-like growth factor-1, transforming growth factor-B, interleukin-1 receptor antagonist, hepatocyte growth factor, platelet-derived growth factor, Indian hedgehog and parathyroid hormone-related peptide or bioactive glue.

The implant material is placed in the lesion area and may be sealed with a periosteum cap.

It is an object of the invention to provide an allograft implant material for joints which provides pain relief, restores normal function and will postpone or alleviate the need for prosthetic replacement.

It is also an object of the invention to provide a cartilage repair implant material which is easily placed in a defect area by the surgeon using an arthroscopic, minimally invasive technique.

It is further an object of the invention to provide an allograft implant material procedure which is applicable for both partial and full thickness lesions.

It is yet another object of the invention to provide an allograft implant material which facilitates growth of hyaline cartilage.

It is an additional object of the invention to provide implant paste and gel material formulations that satisfy surgical requirements and are made from donated human available allograft tissue, some of which would otherwise be considered waste and thrown away.

These and other objects, advantages, and novel features of the present invention will become apparent when considered with the teachings contained in the detailed disclosure along with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the anatomy of a knee joint with a lesion;

FIG. 2 shows a schematic mosaicplasty as known in the prior art; and

FIG. 3 shows a schematic perspective view of cartilage defect material placed in a defect site with an exploded periosteum cap.

 DESCRIPTION OF THE INVENTION

The terms “tissue” is used in the general sense herein to mean any transplantable or implantable tissue, the survivability of which is improved by the methods described herein upon implantation. In particular, the overall durability and longevity of the implant are improved, and host-immune system mediated responses, are substantially eliminated.

The terms “transplant” and “implant” are used interchangably to refer to tissue, material or cells (xenogeneic or allogeneic) which may be introduced into the body of a patient to replace or supplement the structure or function of the endogenous tissue.

The terms “autologous” and “autograft” refer to tissue or cells which originate with or are derived from the recipient, whereas the terms “allogeneic” and “allograft” refer to cells and tissue which originate with or are derived from a donor of the same species as the recipient. The terms “xenogeneic” and “xenograft” refer to cells or tissue which originates with or is derived from a species other than that of the recipient.

The term “gel” refers to a mixture of minced or milled pretreated allograft cartilage in a biocomposite carrier having a viscosity which is less than and is less rigid than a mixture of minced or milled pretreated allograft cartilage in a biocompatible carrier referred to by the terms “putty” or “paste” and contains less cartilage by weight than putty or paste.

The present invention is directed towards a cartilage repair material and method of treatment. The preferred embodiment and best mode of the invention is shown in FIG. 3. In the production of the invention, allograft hyaline cartilage is lyophilized reducing its water content and milled for ease in application.

After washes with sterile de-ionized (DI) water, the cartilage material was frozen at −20° to −100° C. preferably −70° C. and lyophilized to reduce the water content within the range of about 0.1% to about 8.0%. The cartilage is frozen with liquid nitrogen and ground into particles.

A lesion or defect is removed by cutting a bore 50 or trimming a lesion in the implant area 100 and filling the bore 50 or lesion area with a milled cartilage mixture 20 of paste or gel consisting together with a biological carrier such as hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran, or polymers and one or more additives namely chondrogenic stimulating factors including, but not limited to growth factors (FGF-2, FGF-5, IGF-1, TGF-β, BMP-2, BMP-7, PDGF, VEGF), human allogenic or autologous chondrocytes, human allogenic cells, human allogenic or autologous bone marrow cells, human allogenic or autologous stem cells, demineralized bone matrix, insulin, insulin-like growth factor-1, interleukin-1 receptor antagonist, hepatocyte growth factor, platelet-derived growth factor, Indian hedgehog and parathyroid hormone-related peptide.

Suitable organic glue material can be used to keep the viscous cartilage mixture 20 fixed in place in the implant area or to affix a periosteal cap 30 in place over the surrounding hyaline cartilage area 100. Suitable organic glue material can be found commercially, such as for example; TISSEEL® or TISSUCOL®) (fibrin based adhesive; Immuno AG, Austria), Adhesive Protein (Sigma Chemical, USA), and Dow Corning Medical Adhesive B (Dow Corning, USA).

EXAMPLE 1

A matrix of minced cartilage putty consisting of minced or milled allograft articular cartilage which has been lyophilized so that its water content ranges from 0.1% to 8.0% with a cartilage content ranging from 25% to 50% by weight is mixed with a carrier of sodium hyaluronate solution (HA) (molecular weight ranging from 7.0×105 to 1.2×106) or any other bioabsorbable carrier such as hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran, or polymers, the carrier ranging from 75% to 50% by weight. The cartilage is milled to a size ranging from 0.01 mm to 1 mm. In gel form, the minced cartilage which has been lyophilized so that its water content ranges from 0.1% to 8.0% ranging from 15% to 30% by weight and the carrier ranges from 85% to 70% by weight. The particle size of the cartilage when milled is less than or equal to 1 mm dry in the previously stated range. The cartilage pieces can be processed to varying particle sizes and the HA or other carrier can have different viscosities depending on the desired consistency of the putty or paste. This cartilage matrix can be deposited into the cartilage defect arthroscopically and fit into the defect where it is held in place by it's own viscosity, mixed with fibrin glue or covered with a periosteal or perichondrial flap, then sealed with biological glue. As with the first two matrices, this matrix can support the previously mentioned chondrogenic factors.

EXAMPLE 2

A matrix of minced cartilage putty consisting of minced or milled allograft cartilage which has been lyophilized so that its water content ranges from 0.1% to 8.0% ranging from 25% to 50% by weight is mixed with a carrier of sodium hyaluronate solution (HA) (7.0×105 to 1.2×106) or any other bioabsorbable carrier such as hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran, or polymers ranging from 75% to 50% by weight. In a gel form, the minced cartilage which has been lyophilized so that its water content ranges from 0.01% to 8.0% ranging from 15% to 30% by weight and the carrier ranges from 85% to 70% by weight. The particle size of the cartilage is less than or equal to 1 mm dry ranging from 0.01 mm to 1 mm. The cartilage pieces can be processed to varying particle sizes and the HA or carrier can have different viscosities depending on the desired consistency of the putty or paste. Autologous or allogenic cells which have been grown outside the patient are inserted by syringe into the matrix before, during or after deposit of the cartilage matrix into the defect area. Such cells include allogenic or autologous bone marrow cells, stem cells and chondrocyte cells. The cellular density of the cells preferably ranges from about 1×108 to 5×108 or from about 100 million to about 500 million cells per cc of putty or gel mixture. This composite material can be injected into the cartilage defect arthroscopically and fit into the defect where it is held in place by it's own viscosity, or covered with a periosteal or perichondrial flap, then sealed with biological glue. As with the first matrix, this matrix can support the previously mentioned chondrogenic factors.

The operation of placing the cartilage composition in a cartilage defect, comprises (a) cutting a patient's tissue at a site of a cartilage defect to remove the diseased area of cartilage; (b) placing a mixture of milled allograft cartilage in a bioabsorbable carrier in the defect area; and (c) placing a periosteal cover over the mixture of the inserted milled allograft cartilage in a bioabsorbable carrier to contain the mixture in the defect area for a predetermined period of time to promote cartilage growth at the defect site. Alternate steps include the addition of growth factors, chondrocytes, bone marrow cells and stem cells.

The principles, preferred embodiments and modes of operation of the present invention have been described in the foregoing specification. However, the invention should not be construed as limited to the particular embodiments which have been described above. Instead, the embodiments described here should be regarded as illustrative rather than restrictive.

Claims

1. A sterile allograft cartilage defect implant repair material for use in human beings, comprising a mixture including lyophilized, freeze-milled allograft cartilage pieces sized less having a size not greater than 1 mm and a bioabsorbable carrier, said cartilage pieces being formed from allograft cartilage that has been lyophilized so that their as to reduce its water content ranges from to an amount within the range of from about 0.1% to about 8.0% in a bioabsorbable carrier by weight.

2. A sterile allograft cartilage defect implant material as claimed in claim 1 wherein said milled cartilage ranges from about 25% to about 50% by weight and said carrier ranges from about 75% to about 50% by weight.

3. A sterile allograft cartilage defect implant material as claimed in claim 1 wherein said milled cartilage ranges from about 15% to about 30% by weight with the carrier ranging from about 85% to about 70% by weight.

4. A sterile allograft cartilage defect implant repair material as claimed in claim 1, wherein said bioabsorbable carrier is selected from the group consisting of sodium hyaluronate and its derivatives hyaluronic acid.

5. A sterile allograft cartilage defect implant repair material as claimed in claim 1, wherein said implant material mixture includes a protein glue.

6. A sterile allograft cartilage defect implant repair material as claimed in claim 1, wherein said implant material mixture includes the addition of autologous chondrocytes to achieve a concentration exceeding the concentration of chondrocytes naturally occurring in the patient at a concentration greater than the concentration of chondrocytes that are naturally present in hyaline cartilage of a human being having an age in the range of from 20 years to 55 years.

7. A sterile allograft cartilage defect implant repair material as claimed in claim 1, wherein said milled allograft cartilage is pieces include hyaline cartilage.

8. A sterile allograft cartilage defect implant repair material as claimed in claim 1, wherein said milled allograft cartilage is fibrosus cartilage pieces include fibrocartilage.

9. A sterile allograft cartilage defect implant repair material as claimed in claim 1, wherein said milled allograft cartilage is pieces include hyaline and fibrosus cartilage fibrocartilage.

10. A sterile allograft cartilage defect implant repair material as claimed in claim 1, including wherein said mixture includes an additive to said implant material consisting of one or more of a selected from the group consisting of a growth factors factor, human allogenic cells, human allogenic bone marrow cells, human autologous bone marrow cells, human allogenic stem cells, human autologous stem cells, a human demineralized bone matrix, and insulin, insulin-like growth factor-1, an interleukin-1, receptor agonist, a hepatocyte growth factor, a platelet-derived growth factor, Indian hedgehog, and a parathryroid hormone-related peptide.

11. A sterile cartilage defect repair material as claimed in claim 10, wherein said growth factors are one or more of a factor is selected from the group consisting of FGF-2, FGF-5, IGF-1, TGF-β, BMP-2, BMP-7, PDGF, and VEGF.

12. A sterile allograft cartilage defect implant repair material as claimed in claim 1, wherein said bioabsorbable carrier comprises one or more bioabsorbable carriers taken is selected from a the group consisting of sodium hyaluronate, hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran, or and polymers.

13. A sterile allograft cartilage defect implant repair material for use in human beings, comprising a mixture including lyophilized, freeze-milled allograft articular cartilage pieces ranging from 0.01 mm to 1.0 mm in size in, a bioabsorbable carrier taken selected from a the group consisting of sodium hyaluronate, hyaluronic acid, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran, or and polymers, and allogenic chondrocytes in an amount exceeding the natural occurrence of same in articular cartilage at a concentration greater than the concentration of chondrocytes that are naturally present in hyaline cartilage of a human being having an age in the range of from 20 years and 55 years.

14. A sterile cartilage defect implant repair material as claimed in claim 13, wherein said allograft articular cartilage is pieces include hyaline cartilage.

15. A sterile allograft cartilage defect implant repair material as claimed in claim 13, wherein said milled allograft articular cartilage is fibrous cartilage pieces include fibrocartilage.

16. A sterile allograft cartilage defect implant repair material as claimed in claim 13, wherein said milled allograft articular cartilage is pieces include hyaline cartilage and fibrous cartilage fibrocartilage.

17. A sterile cartilage defect repair material as claimed in claim 13 wherein said implant material includes, further comprising an additive consisting of one or more of a selected from the group consisting of a growth factors factor, human allogenic cells, human allogenic bone marrow cells, human autologous bone marrow cells, human allogenic stem cells, human autologous stem cells, demineralized bone matrix, and insulin, insulin-like growth factor-1, interleukin-1 receptor agonist, hepatocyte growth factor, platelet-derived growth factor, Indian hedgehog, and parathyroid hormone-related peptide.

18. A sterile cartilage defect repair material as claimed in claim 17, wherein said growth factors are one or more of a factor is selected from the group consisting of FGF-2, FGF-5, IGF-1, TGF-β, BMP-2, BMP-7, PDGF, and VEGF.

19. A sterile cartilage defect implant material as claimed in claim 13 wherein said milled cartilage ranges from about 25% to about 50% by weight and said carrier ranges from about 75% to about 50% by weight.

20. A sterile cartilage defect implant material as claimed in claim 13 wherein said milled cartilage ranges from about 15% to about 30% by weight with the carrier ranging from about 85% to about 70% by weight.

21. A sterile allograft cartilage defect implant repair material for use in human beings, comprising lyophilized, freeze-milled allograft articular cartilage pieces ranging from 0.01 mm to 1.0 mm in size in, a bioabsorbable carrier taken selected from a the group consisting of sodium hyaluronate, hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran or, and polymers, and autologous bone marrow cells in an amount exceeding the natural occurrence of same in a patient being treated at a concentration greater than the concentration of bone marrow cells that are naturally present in hyaline cartilage of a human being having an age in the range of from 20 years to 55 years.

22. A sterile cartilage defect repair material as claimed in claim 21 including, further comprising an additive in said implant material which consists of one or more of a selected from the group consisting of a growth factors factor, human allogenic cells, autologous chondrocytes, demineralized bone matrix, and insulin, insulin-like growth factor-1, an interleukin-1 receptor agonist, a hepatocyte growth factor, a platelet-derived growth factor, Indian hedgehog, and a parathyroid hormone-related peptide.

23. A sterile cartilage defect repair material as claimed in claim 22, wherein said growth factors are one or more of a factor is selected from the group consisting of FGF-2, FGF-5, IGF-1, TGF-β, BMP-2, BMP-7, PDGF, and VEGF.

24. A sterile allograft cartilage defect implant repair material as claimed in claim 21, wherein said bioabsorbable carrier consists is selected from the group consisting of sodium hyaluronate, and hyaluronic acid and its derivatives.

25. A sterile cartilage defect repair material as claimed in claim 21; wherein said lyophilized allograft articular cartilage pieces have ranging from are formed from allograft articular cartilage that has been lyophilized so as to reduce its water content to the range of about 0.1% to about 8.0%.

26. A sterile allograft cartilage defect implant repair material as claimed in claim 21, wherein said allograft articular cartilage is pieces include hyaline cartilage.

27. A sterile allograft cartilage defect implant repair material as claimed in claim 21, wherein said milled allograft articular cartilage is fibrous cartilage pieces include fibrocartilage.

28. A sterile allograft cartilage defect implant repair material as claimed in claim 21, wherein said milled allograft articular cartilage is pieces include hyaline cartilage and fibrous cartilage fibrocartilage.

29. A sterile allograft cartilage defect implant repair material as claimed in claim 21, wherein said milled allograft articular cartilage ranges pieces are present in said material at an amount in the range of from about 25% to about 50% by weight and said bioabsorbable carrier ranges is present in said material at an amount in the range of from about 75% 50% to about 50% 75% by weight.

30. A sterile allograft cartilage defect implant repair material as claimed in claim 21, wherein said milled allograft articular cartilage ranges pieces are present in said material in an amount in the range of from about 15% to about 30% by weight with the and said bioabsorbable carrier ranging is present in said material in an amount in the range of from about 85% 70% to about 70% 85% by weight.

31. A sterile cartilage defect implant material comprising lyophilized milled allograft articular cartilage pieces ranging from 0.01 mm to 1.0 mm in size in a bioabsorbable carrier taken from a group consisting of sodium hyaluronate, hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran or polymers and autologous stem cells in an amount exceeding the natural occurrence of same in a patient being treated.

32. A method of placing a cartilage defect repair material in a cartilage defect site in a human being, said the cartilage defect repair material comprising having a mixture including lyophilized freeze-milled allograft articular cartilage which has been lyophilized and mixed in pieces and a bioabsorbable carrier, said method comprising the steps of:

(a) cutting a patient's tissue at a site of a cartilage defect to remove a diseased area of cartilage from the cartilage defect site;
(b) adding autologous cells to said the mixture of milled allograft cartilage in a bioabsorbable carrier;
(c) placing a the mixture of milled allograft cartilage with the added autologous cells in a bioabsorbable carrier in into the cartilage defect area where cartilage has been removed site; and
(d) placing a cover over the mixture of milled allograft cartilage in a bioabsorbable carrier and the added cells so as to contain the mixture and the added cells in the cartilage defect site for a predetermined period of time.

33. The method of claim 32, wherein further comprising the step of adding growth factors are added to said the mixture.

34. The method of claim 32, wherein said autologous cells are include chondrocytes.

35. The method of claim 32, wherein said autologous cells are include bone marrow cells.

36. The method of claim 32, wherein said autologous cells are include stem cells.

37. A sterile allograft cartilage defect implant repair material for use in a human being, comprising a mixture including lyophilized, freeze-milled allograft articular cartilage pieces ranging from 0.01 mm to 1.0 mm in size in, a bioabsorbable carrier taken selected from a the group consisting of sodium hyaluronate, hyaluronic acid and its derivatives, and chitosan, and autologous chondrocytes in an amount exceeding the natural occurrence of same in articular cartilage at a concentration greater than the concentration of chondrocytes that are naturally present in hyaline cartilage of a human being having an age in the range of from 20 years and 55 years, wherein said milled allograft articular cartilage ranges pieces are present in said mixture at an amount within the range of from about 25% to about 50% by weight and said bioabsorbable carrier ranges is present in said mixture at an amount within the range of from about 75% 50% to about 50% 75% by weight.

38. A sterile allograft cartilage defect implant repair material for use in a human being, comprising a mixture including lyophilized, freeze-milled allograft articular cartilage pieces ranging from 0.01 mm to 1.0 mm in size in, a bioabsorbable carrier taken selected from a the group consisting of gelatin, collagen, and alginate, and autologous chondrocytes in an amount exceeding the natural occurrence of same in articular cartilage at a concentration greater than the concentration of chondrocytes that are naturally present in hyaline cartilage of a human being having an age in the range of from 20 years and 55 years, wherein said milled allograft articular cartilage ranges pieces are present in said mixture at an amount within the range of from about 25% to about 50% by weight and said bioabsorbable carrier ranges is present in said mixture at an amount within the range of from about 75% 50% to about 50% 75% by weight.

39. A sterile allograft cartilage defect implant repair material for use in a human being, comprising a mixture including lyophilized, freeze-milled allograft articular cartilage pieces ranging from 0.01 mm to 1.0 mm in size in, a bioabsorbable carrier taken selected from a the group consisting of buffered PBS, Dextran or, and polymers, and autologous chondrocytes in an amount exceeding the natural occurrence of same in articular cartilage at a concentration greater than the concentration of chondrocytes that are naturally present in hyaline cartilage of a human being having an age in the range of from 20 years and 55 years, wherein said milled allograft articular cartilage ranges pieces are present in said mixture at an amount within the range of from about 25% to about 50% by weight and said bioabsorbable carrier ranges is present in said mixture at an amount within the range of from about 75% 50% to about 50% 75% by weight.

40. A cartilage defect repair material as claimed in claim 1, wherein said cartilage pieces are present in said mixture at an amount within the range of from about 25% to about 50% by weight, and said bioabsorbable carrier is present in said mixture at an amount within the range of from about 50% to about 75% by weight.

41. A cartilage defect repair material as claimed in claim 1, wherein said cartilage pieces are present in said mixture at an amount within the range of from about 15% to about 30% by weight, and said bioabsorbable carrier is present in said mixture at an amount within the range of from about 70% to about 85% by weight.

42. A cartilage defect repair material as claimed in claim 1, wherein said lyophilized. freeze-milled allograft cartilage pieces lack cell viability.

43. A cartilage defect repair material as claimed in claim 1, wherein said cartilage defect repair material is free of bone pieces.

44. A cartilage defect repair material as claimed in claim 1, wherein said lyophilized, freeze-milled allograft cartilage pieces are formed by a process including the steps of harvesting a donor tissue consisting essentially of articular cartilage, lyophilizing said donor tissue, and freeze-milling said donor tissue.

45. A cartilage defect repair material as claimed in claim 1, wherein said lyophilized, freeze-milled allograft cartilage pieces are formed by milling frozen allograft articular cartilage.

46. A cartilage defect repair material as claimed in claim 1, wherein said lyophilized, freeze-milled cartilage pieces are formed by freezing allograft cartilage with liquid nitrogen and milling the frozen cartilage.

47. A cartilage defect repair material as claimed in claim 1, wherein said cartilage defect repair material is free of added chondrocytes.

48. A cartilage defect repair material as claimed in claim 1, wherein said lyophilized, freeze-milled allograft cartilage pieces have an ability to promote the growth of new articular cartilage in the cartilage defect.

49. A cartilage defect repair material as claimed in claim 13, wherein said mixture includes a protein glue.

50. A cartilage defect repair material as claimed in claim 13, wherein said allograft articular cartilage pieces are formed from allograft articular cartilage that has been lyophilized so as to reduce its water content to the range of from about 0.1% to about 8.0% by weight.

51. A cartilage defect repair material as claimed in claim 13, wherein said cartilage pieces are present in said mixture at an amount within the range of from about 25% to about 50% by weight, and said bioabsorbable carrier is present in said mixture at an amount within the range of from about 50% to about 75% by weight.

52. A cartilage defect repair material as claimed in claim 13, wherein said cartilage pieces are present in said mixture at an amount within the range of from about 15% to about 30% by weight, and said bioabsorbable carrier is present in said mixture at an amount within the range of from about 70% to about 85% by weight.

53. A cartilage defect repair material as claimed in claim 21, further comprising a protein glue.

54. The method of claim 32, further comprising the step of fixing the mixture in the cartilage defect site with an organic glue.

55. The method of claim 32, further comprising the step of keeping the cover over the mixture for a predetermined period of time that is sufficient to promote cartilage growth at the cartilage defect site.

56. The method of claim 32, wherein said cover is a periosteal flap.

57. The method of claim 32, wherein said cover is a perichondrial flap.

58. The method of claim 32, wherein, in said step (b), the cells are selected from the group consisting of chondrocytes, bone marrow cells and stem cells, and the cells are added so as to achieve a concentration greater than the concentration of corresponding cells that are naturally present in hyaline cartilage of a human being having an age in the range of from 20 years and 55 years.

59. A cartilage defect repair material for use in human beings, comprising lyophilized, freeze-milled allograft cartilage pieces having a size not greater than 1 mm, wherein said cartilage pieces are included in a mixture that also includes a bioabsorbable carrier, said cartilage pieces being present in said mixture at an amount within the range of from about 25% to about 50% by weight, and said bioabsorbable carrier being present in said mixture at an amount within the range of from about 50% to about 75% by weight.

60. A cartilage defect repair material as claimed in claim 59, wherein said cartilage pieces are formed from allograft cartilage that has been lyophilized so as to reduce its water content to an amount within the range of from about 0.1% to about 8.0% by weight.

61. A cartilage defect repair material as claimed in claim 59, wherein said size ranges from 0.01 mm to 1.0 mm.

62. A cartilage defect repair material as claimed in claim 59, wherein said material is free of added chondrocytes.

63. A cartilage defect repair material as claimed in claim 59, wherein said cartilage pieces are formed by freezing allograft cartilage with liquid nitrogen and milling the frozen cartilage.

64. A cartilage defect repair material as claimed in claim 59, wherein said cartilage pieces are formed by freeze-milling allograft cartilage subsequent to lyophilization.

65. A cartilage defect repair material for use in human beings, comprising lyophilized, freeze-milled allograft cartilage pieces having a size not greater than 1 mm, wherein said cartilage pieces are included in a mixture that also includes a bioabsorbable carrier, said cartilage pieces being present in said mixture at an amount within the range of from about 15% to about 30% by weight, and said bioabsorbable carrier being present in said mixture at an amount within the range of from about 70% to about 85% by weight.

66. A cartilage defect repair material as claimed in claim 65, wherein said cartilage pieces are formed from allograft cartilage that has been lyophilized so as to reduce its water content to an amount within the range of from about 0.1% to about 8.0% by weight.

67. A cartilage defect repair material as claimed in claim 65, wherein said size ranges from 0.01 mm to 1.0 mm.

68. A cartilage defect repair material as claimed in claim 65, wherein said material is free of added chondrocytes.

69. A cartilage defect repair material as claimed in claim 65, wherein said cartilage pieces are formed by freezing allograft cartilage with liquid nitrogen and milling the frozen cartilage.

70. A cartilage defect repair material as claimed in claim 65, wherein said cartilage pieces are formed by freeze-milling allograft cartilage subsequent to lyophilization.

71. A method of repairing a cartilage defect in a human being, comprising the step of placing in a defect site lyophilized, freeze-milled allograft cartilage pieces having a size not greater than 1 mm.

72. A method as claimed in claim 71, wherein the cartilage pieces have a water content ranging from about 0.1% to about 8.0% by weight prior to their placement in the defect site.

73. A method as claimed in claim 71, wherein the cartilage pieces are formed from allograft cartilage which has been lyophilized so as to reduce its water content to an amount within the range of from about 0.1% to about 8.0% by weight.

74. A method as claimed in claim 71, wherein the size ranges from 0.01 mm to 1.0 mm.

75. A method as claimed in claim 71, wherein the cartilage pieces are formed by freezing allograft cartilage with liquid nitrogen and milling the frozen cartilage.

76. A method as claimed in claim 71, wherein the cartilage pieces are formed by freeze-milling allograft cartilage subsequent to lyophilization of the allograft cartilage.

77. A method as claimed in claim 71, wherein the defect site includes a defect in articular cartilage.

78. A method as claimed in claim 77, wherein the cartilage pieces have an ability to promote the growth of new articular cartilage in the articular cartilage defect.

79. A method as claimed in claim 71, wherein the lyophilized, freeze-milled allograft cartilage pieces consist essentially of articular cartilage.

80. A method as claimed in claim 71, wherein the lyophilized, freeze-milled allograft cartilage pieces lack cell viability.

81. A method as claimed in claim 71, comprising the further steps of harvesting a donor tissue consisting essentially of articular cartilage, lyophilizing said donor tissue, and freeze-milling said donor tissue.

82. A method as claimed in claim 71, comprising the further step of forming the lyophilized, freeze-milled allograft cartilage pieces by a process including the step of milling frozen allograft articular cartilage.

83. A method as claimed in claim 71, wherein the lyophilized, freeze-milled allograft cartilage pieces are free of added chondrocytes.

Referenced Cited
U.S. Patent Documents
3400199 September 1968 Balassa
3551560 December 1970 Theile
3772432 November 1973 Balassa
3867728 February 1975 Stubstad et al.
3966908 June 29, 1976 Balassa
4060081 November 29, 1977 Yannas et al.
4172128 October 23, 1979 Thiele et al.
4201845 May 6, 1980 Feder et al.
4296100 October 20, 1981 Franco
4378347 March 29, 1983 Franco
4394370 July 19, 1983 Jefferies
4400833 August 30, 1983 Kurland
4442655 April 17, 1984 Stroetmann
4458678 July 10, 1984 Yannas et al.
4479271 October 30, 1984 Bolesky et al.
4501269 February 26, 1985 Bagby
4505266 March 19, 1985 Yannas et al.
4600574 July 15, 1986 Lindner et al.
4627853 December 9, 1986 Campbell et al.
4642120 February 10, 1987 Nevo et al.
4656137 April 7, 1987 Balassa
4681763 July 21, 1987 Nathanson et al.
4683195 July 28, 1987 Mullis et al.
4683202 July 28, 1987 Mullis
4757017 July 12, 1988 Cheung
4776173 October 11, 1988 Kamarei et al.
4776853 October 11, 1988 Klement et al.
4795467 January 3, 1989 Piez et al.
4801299 January 31, 1989 Brendel et al.
4837379 June 6, 1989 Weinberg
4846835 July 11, 1989 Grande
4880429 November 14, 1989 Stone
4902508 February 20, 1990 Badylak et al.
4904259 February 27, 1990 Itay
4932973 June 12, 1990 Gendler
4950296 August 21, 1990 McIntyre
4950483 August 21, 1990 Ksander et al.
4955911 September 11, 1990 Frey et al.
4963146 October 16, 1990 Li
4965188 October 23, 1990 Mullis et al.
4971954 November 20, 1990 Brodsky et al.
4976738 December 11, 1990 Frey et al.
4978355 December 18, 1990 Frey et al.
4994084 February 19, 1991 Brennan
4994559 February 19, 1991 Moscatelli et al.
5002583 March 26, 1991 Pitaru et al.
5007934 April 16, 1991 Stone
5041138 August 20, 1991 Vacanti et al.
5053049 October 1, 1991 Campbell
5053050 October 1, 1991 Itay
5067964 November 26, 1991 Richmond et al.
5073373 December 17, 1991 O'Leary et al.
5084051 January 28, 1992 Tormala et al.
5118512 June 2, 1992 O'Leary
5152791 October 6, 1992 Hakamatsuka et al.
5155214 October 13, 1992 Baird et al.
5191067 March 2, 1993 Lappi et al.
5195892 March 23, 1993 Gershberg
5206023 April 27, 1993 Hunziker
5236456 August 17, 1993 O'Leary et al.
5256140 October 26, 1993 Fallick
5260420 November 9, 1993 Burnouf-Radosevich et al.
5266476 November 30, 1993 Sussman et al.
5270300 December 14, 1993 Hunziker
5275826 January 4, 1994 Badylak et al.
5284155 February 8, 1994 Treadwell et al.
5290558 March 1, 1994 O'Leary et al.
5298254 March 29, 1994 Prewett et al.
5302702 April 12, 1994 Seddon et al.
5306304 April 26, 1994 Gendler
5306311 April 26, 1994 Stone et al.
5310883 May 10, 1994 Seddon et al.
5314476 May 24, 1994 Prewett et al.
5326357 July 5, 1994 Kandel
5329846 July 19, 1994 Bonutti
5336616 August 9, 1994 Livesey et al.
5338772 August 16, 1994 Bauer et al.
5352463 October 4, 1994 Badylak et al.
5354557 October 11, 1994 Oppermann et al.
5356629 October 18, 1994 Sander et al.
5368858 November 29, 1994 Hunziker
5380328 January 10, 1995 Morgan
5411885 May 2, 1995 Marx
5425769 June 20, 1995 Snyders, Jr.
5439684 August 8, 1995 Prewett et al.
5439818 August 8, 1995 Fiddes et al.
5443950 August 22, 1995 Naughton et al.
5464439 November 7, 1995 Gendler
5466462 November 14, 1995 Rosenthal et al.
5491220 February 13, 1996 Seddon et al.
5496722 March 5, 1996 Goodwin et al.
5507813 April 16, 1996 Dowd et al.
5512460 April 30, 1996 Nauro et al.
5513662 May 7, 1996 Morse et al.
5516532 May 14, 1996 Atala et al.
5556430 September 17, 1996 Gendler
5569272 October 29, 1996 Reed et al.
5571895 November 5, 1996 Kurokawa et al.
5576288 November 19, 1996 Lappi et al.
5604293 February 18, 1997 Fiddes et al.
5607474 March 4, 1997 Athanasiou et al.
5614496 March 25, 1997 Dunstan et al.
5618925 April 8, 1997 Dupont et al.
5622928 April 22, 1997 Naruo et al.
5624463 April 29, 1997 Stone et al.
5631011 May 20, 1997 Wadstrom
5632745 May 27, 1997 Schwartz
5656598 August 12, 1997 Dunstan et al.
5662710 September 2, 1997 Bonutti
5679637 October 21, 1997 Lappi et al.
5695998 December 9, 1997 Badylak et al.
5700476 December 23, 1997 Rosenthal et al.
5700774 December 23, 1997 Hattersley et al.
5707962 January 13, 1998 Chen et al.
5713374 February 3, 1998 Pachence et al.
5716413 February 10, 1998 Walter et al.
5723331 March 3, 1998 Tubo et al.
5736372 April 7, 1998 Vacanti et al.
5749874 May 12, 1998 Schwartz
5759190 June 2, 1998 Vibe-Hansen et al.
5769899 June 23, 1998 Schwartz et al.
5770417 June 23, 1998 Vacanti et al.
5782835 July 21, 1998 Hart et al.
5782915 July 21, 1998 Stone
5786217 July 28, 1998 Tubo et al.
5800537 September 1, 1998 Bell
5814084 September 29, 1998 Grivas et al.
5842477 December 1, 1998 Naughton et al.
5846931 December 8, 1998 Hattersley et al.
5853746 December 29, 1998 Hunziker
5855620 January 5, 1999 Bishopric et al.
5859208 January 12, 1999 Fiddes et al.
5863296 January 26, 1999 Orton
5863297 January 26, 1999 Walter et al.
5866415 February 2, 1999 Villeneuve
5876452 March 2, 1999 Athanasiou et al.
5888219 March 30, 1999 Bonutti
5893888 April 13, 1999 Bell
5899936 May 4, 1999 Goldstein
5904716 May 18, 1999 Gendler
5906827 May 25, 1999 Khouri et al.
5910315 June 8, 1999 Stevenson et al.
5916265 June 29, 1999 Hu
5948429 September 7, 1999 Bell et al.
5955438 September 21, 1999 Pitaru et al.
5964805 October 12, 1999 Stone
5968556 October 19, 1999 Atala et al.
5972368 October 26, 1999 McKay
5972385 October 26, 1999 Liu et al.
5974663 November 2, 1999 Ikeda et al.
5989269 November 23, 1999 Vibe-Hansen et al.
5989289 November 23, 1999 Coates et al.
5989866 November 23, 1999 Deisher et al.
5998170 December 7, 1999 Arakawa et al.
6001352 December 14, 1999 Boyan et al.
6005161 December 21, 1999 Brekke et al.
6013853 January 11, 2000 Athanasiou et al.
6017348 January 25, 2000 Hart et al.
6025334 February 15, 2000 Dupont et al.
6025538 February 15, 2000 Yaccarino, III
6027743 February 22, 2000 Khouri et al.
6030635 February 29, 2000 Gertzman et al.
6037171 March 14, 2000 Larsson
6039762 March 21, 2000 McKay
6060640 May 9, 2000 Pauley et al.
6074663 June 13, 2000 Delmotte et al.
6080194 June 27, 2000 Pachence et al.
6090996 July 18, 2000 Li
6090998 July 18, 2000 Grooms et al.
6096081 August 1, 2000 Grivas et al.
6096347 August 1, 2000 Geddes et al.
6110209 August 29, 2000 Stone
6110482 August 29, 2000 Khouri et al.
6123731 September 26, 2000 Boyce et al.
6132472 October 17, 2000 Bonutti
6143293 November 7, 2000 Weiss et al.
6156068 December 5, 2000 Walter et al.
6165486 December 26, 2000 Marra et al.
6165487 December 26, 2000 Ashkar et al.
6180605 January 30, 2001 Chen et al.
6183737 February 6, 2001 Zaleske et al.
6189537 February 20, 2001 Wolfinbarger, Jr.
6197586 March 6, 2001 Bhatnagar et al.
6200347 March 13, 2001 Anderson et al.
6221854 April 24, 2001 Radomsky
6231607 May 15, 2001 Ben-Bassat et al.
6235316 May 22, 2001 Adkisson
6242247 June 5, 2001 Rieser et al.
6251143 June 26, 2001 Schwartz et al.
6258778 July 10, 2001 Rodgers et al.
6261586 July 17, 2001 McKay
6267786 July 31, 2001 Stone
6270528 August 7, 2001 McKay
6274090 August 14, 2001 Coelho et al.
6274663 August 14, 2001 Hosokawa et al.
6274712 August 14, 2001 Springer et al.
6280473 August 28, 2001 Lemperle et al.
6281195 August 28, 2001 Rueger et al.
6283980 September 4, 2001 Vibe-Hansen et al.
6293970 September 25, 2001 Wolfinbarger, Jr.
6294187 September 25, 2001 Boyce et al.
6294359 September 25, 2001 Fiddes et al.
6303585 October 16, 2001 Spiro et al.
6305379 October 23, 2001 Wolfinbarger, Jr.
6306174 October 23, 2001 Gie et al.
6306424 October 23, 2001 Vyakarnam et al.
6310267 October 30, 2001 Rapp
6319712 November 20, 2001 Meenen et al.
6333029 December 25, 2001 Vyakarnam et al.
6352558 March 5, 2002 Spector
6352971 March 5, 2002 Deisher et al.
6361565 March 26, 2002 Bonutti
6376244 April 23, 2002 Atala
6379367 April 30, 2002 Vibe-Hansen et al.
6379385 April 30, 2002 Kalas et al.
6383221 May 7, 2002 Scarborough
6387693 May 14, 2002 Rieser et al.
6398811 June 4, 2002 McKay
6398816 June 4, 2002 Breitbart et al.
6398972 June 4, 2002 Blasetti et al.
6432436 August 13, 2002 Gertzman et al.
6437018 August 20, 2002 Gertzman et al.
6440141 August 27, 2002 Philippon
6440427 August 27, 2002 Wadstrom
6440444 August 27, 2002 Boyce et al.
6454811 September 24, 2002 Sherwood et al.
6458144 October 1, 2002 Morris et al.
6458158 October 1, 2002 Anderson et al.
6458375 October 1, 2002 Gertzman et al.
6468314 October 22, 2002 Schwartz
6471993 October 29, 2002 Shastri et al.
6475175 November 5, 2002 Rivera et al.
6486377 November 26, 2002 Rapp
6488033 December 3, 2002 Cerundolo
6489165 December 3, 2002 Bhatnagar
6497726 December 24, 2002 Carter et al.
6503277 January 7, 2003 Bonutti
6511511 January 28, 2003 Slivka et al.
6511958 January 28, 2003 Atkinson et al.
6514514 February 4, 2003 Atkinson et al.
6520964 February 18, 2003 Tallarida et al.
6530956 March 11, 2003 Mansmann
6534084 March 18, 2003 Vyakarnam et al.
6541024 April 1, 2003 Kadiyala et al.
6548729 April 15, 2003 Seelich et al.
6569172 May 27, 2003 Asculai et al.
6576015 June 10, 2003 Geistlich et al.
6582960 June 24, 2003 Martin et al.
6591581 July 15, 2003 Schmieding
6592598 July 15, 2003 Vibe-Hansen et al.
6592599 July 15, 2003 Vibe-Hansen et al.
6599300 July 29, 2003 Vibe-Hansen et al.
6599301 July 29, 2003 Vibe-Hansen et al.
6599515 July 29, 2003 Delmotte
6623963 September 23, 2003 Muller et al.
6626950 September 30, 2003 Brown et al.
6630000 October 7, 2003 Bonutti
6632247 October 14, 2003 Boyer, II et al.
6652592 November 25, 2003 Grooms et al.
6652593 November 25, 2003 Boyer, II et al.
6652872 November 25, 2003 Nevo et al.
6662805 December 16, 2003 Frondoza et al.
6666892 December 23, 2003 Hiles et al.
6686184 February 3, 2004 Anderson et al.
6689747 February 10, 2004 Filvaroff et al.
6696073 February 24, 2004 Boyce et al.
6712851 March 30, 2004 Lemperle et al.
6727224 April 27, 2004 Zhang et al.
6730314 May 4, 2004 Jeschke et al.
6734018 May 11, 2004 Wolfinbarger, Jr. et al.
6743232 June 1, 2004 Overaker et al.
6752834 June 22, 2004 Geistlich et al.
6761739 July 13, 2004 Shepard
6761887 July 13, 2004 Kavalkovich et al.
6767369 July 27, 2004 Boyer, II et al.
6776800 August 17, 2004 Boyer, II et al.
6783712 August 31, 2004 Slivka et al.
6808585 October 26, 2004 Boyce et al.
6815416 November 9, 2004 Carney et al.
6838440 January 4, 2005 Stiles
6841150 January 11, 2005 Halvorsen et al.
6852114 February 8, 2005 Cerundolo
6852125 February 8, 2005 Simon et al.
6852331 February 8, 2005 Lai et al.
6855167 February 15, 2005 Shimp et al.
6855169 February 15, 2005 Boyer, II et al.
6858042 February 22, 2005 Nadler et al.
6866668 March 15, 2005 Giannetti et al.
6884428 April 26, 2005 Binette et al.
6890354 May 10, 2005 Steiner et al.
6893462 May 17, 2005 Buskirk et al.
6902578 June 7, 2005 Anderson et al.
6911212 June 28, 2005 Gertzman et al.
6932977 August 23, 2005 Heidaran et al.
6933326 August 23, 2005 Griffey et al.
6933328 August 23, 2005 Schacht
6949252 September 27, 2005 Mizuno et al.
6989034 January 24, 2006 Hammer et al.
6995013 February 7, 2006 Connelly et al.
7009039 March 7, 2006 Yayon et al.
7018416 March 28, 2006 Hanson et al.
7033587 April 25, 2006 Halvorsen et al.
7041641 May 9, 2006 Rueger et al.
7044968 May 16, 2006 Yaccarino, III et al.
7045141 May 16, 2006 Merboth et al.
7048750 May 23, 2006 Vibe-Hansen et al.
7048762 May 23, 2006 Sander et al.
7048765 May 23, 2006 Grooms et al.
7067123 June 27, 2006 Gomes et al.
7070942 July 4, 2006 Heidaran et al.
7078232 July 18, 2006 Konkle et al.
7108721 September 19, 2006 Huckle et al.
RE39321 October 3, 2006 MacPhee et al.
7115146 October 3, 2006 Boyer, II et al.
7125423 October 24, 2006 Hazebrouck
7132110 November 7, 2006 Kay et al.
7137989 November 21, 2006 Asculai et al.
7141072 November 28, 2006 Coeistlich
7156880 January 2, 2007 Evans et al.
7157428 January 2, 2007 Kusanagi et al.
7163563 January 16, 2007 Schwartz et al.
7166133 January 23, 2007 Evans et al.
7179299 February 20, 2007 Edwards et al.
7182781 February 27, 2007 Bianchi et al.
7201917 April 10, 2007 Malaviya et al.
7217294 May 15, 2007 Kusanagi et al.
7220558 May 22, 2007 Luyten et al.
7241316 July 10, 2007 Evans et al.
7252987 August 7, 2007 Bachalo et al.
7264634 September 4, 2007 Schmieding
7288406 October 30, 2007 Bogin et al.
7291169 November 6, 2007 Hodorek
7297161 November 20, 2007 Fell
7316822 January 8, 2008 Binette et al.
7323011 January 29, 2008 Shepard et al.
7323445 January 29, 2008 Zhang et al.
7335508 February 26, 2008 Yayon et al.
7338492 March 4, 2008 Singhatat
7338524 March 4, 2008 Fell et al.
7358284 April 15, 2008 Griffey et al.
7361195 April 22, 2008 Schwartz et al.
7365051 April 29, 2008 Paulista et al.
7371400 May 13, 2008 Borenstein et al.
7416889 August 26, 2008 Ciombor et al.
7468075 December 23, 2008 Lang et al.
7468192 December 23, 2008 Mizuno et al.
7479160 January 20, 2009 Branch et al.
7485310 February 3, 2009 Luyten et al.
7488348 February 10, 2009 Truncale et al.
7513910 April 7, 2009 Buskirk et al.
7531000 May 12, 2009 Hodorek
7537617 May 26, 2009 Bindsell et al.
7537780 May 26, 2009 Mizuno et al.
7550007 June 23, 2009 Malinin
7563455 July 21, 2009 McKay
7563769 July 21, 2009 Bogin et al.
7601173 October 13, 2009 Messerli et al.
7608113 October 27, 2009 Boyer, II et al.
7621963 November 24, 2009 Simon et al.
7622438 November 24, 2009 Lazarov et al.
7622562 November 24, 2009 Thorne et al.
7628851 December 8, 2009 Armitage et al.
7632311 December 15, 2009 Seedhom et al.
7638486 December 29, 2009 Lazarov et al.
7642092 January 5, 2010 Maor
7648700 January 19, 2010 Vignery et al.
7648965 January 19, 2010 Vignery et al.
7658768 February 9, 2010 Miller et al.
7662184 February 16, 2010 Edwards et al.
7666230 February 23, 2010 Orban et al.
20010005592 June 28, 2001 Bhatnagar et al.
20010006634 July 5, 2001 Zaleske et al.
20010010023 July 26, 2001 Schwartz et al.
20010011131 August 2, 2001 Luyten et al.
20010016646 August 23, 2001 Rueger et al.
20010018619 August 30, 2001 Enzerink et al.
20010020188 September 6, 2001 Sander
20010021875 September 13, 2001 Enzerink et al.
20010031254 October 18, 2001 Bianchi et al.
20010039457 November 8, 2001 Boyer, II et al.
20010039458 November 8, 2001 Boyer, II et al.
20010043940 November 22, 2001 Boyce et al.
20010051834 December 13, 2001 Frondoza et al.
20020009805 January 24, 2002 Nevo et al.
20020016592 February 7, 2002 Branch et al.
20020035401 March 21, 2002 Boyce et al.
20020042373 April 11, 2002 Carney et al.
20020045940 April 18, 2002 Giannetti et al.
20020055783 May 9, 2002 Tallarida et al.
20020072806 June 13, 2002 Buskirk et al.
20020082704 June 27, 2002 Cerundolo
20020099448 July 25, 2002 Hiles et al.
20020106393 August 8, 2002 Bianchi et al.
20020111695 August 15, 2002 Kandel
20020120274 August 29, 2002 Overaker et al.
20020138143 September 26, 2002 Grooms et al.
20020177224 November 28, 2002 Madry et al.
20020192263 December 19, 2002 Merboth et al.
20030021827 January 30, 2003 Malaviya et al.
20030023316 January 30, 2003 Brown et al.
20030032961 February 13, 2003 Pelo et al.
20030033021 February 13, 2003 Plouhar et al.
20030033022 February 13, 2003 Plouhar et al.
20030036797 February 20, 2003 Malaviya et al.
20030036801 February 20, 2003 Schwartz et al.
20030039695 February 27, 2003 Geistlich et al.
20030040113 February 27, 2003 Mizuno et al.
20030044444 March 6, 2003 Malaviya et al.
20030049299 March 13, 2003 Malaviya et al.
20030050709 March 13, 2003 Noth et al.
20030055502 March 20, 2003 Lang et al.
20030078617 April 24, 2003 Schwartz et al.
20030099620 May 29, 2003 Zaleske et al.
20030144743 July 31, 2003 Edwards et al.
20030229400 December 11, 2003 Masuda et al.
20030236573 December 25, 2003 Evans et al.
20040028717 February 12, 2004 Sittinger et al.
20040033212 February 19, 2004 Thomson et al.
20040039447 February 26, 2004 Simon et al.
20040044408 March 4, 2004 Hungerford et al.
20040062753 April 1, 2004 Rezania et al.
20040078090 April 22, 2004 Binette et al.
20040102850 May 27, 2004 Shepard
20040115172 June 17, 2004 Bianchi et al.
20040134502 July 15, 2004 Mizuno et al.
20040138748 July 15, 2004 Boyer, II et al.
20040143344 July 22, 2004 Malaviya et al.
20040151705 August 5, 2004 Mizuno et al.
20040166169 August 26, 2004 Malaviya et al.
20040170610 September 2, 2004 Slavin et al.
20040175826 September 9, 2004 Maor
20040192605 September 30, 2004 Renwen et al.
20040193268 September 30, 2004 Hazebrouck
20040197311 October 7, 2004 Brekke et al.
20040197373 October 7, 2004 Gertzman et al.
20040219182 November 4, 2004 Gomes et al.
20040220574 November 4, 2004 Pelo et al.
20040230303 November 18, 2004 Gomes et al.
20040243242 December 2, 2004 Sybert et al.
20050004672 January 6, 2005 Pafford et al.
20050020500 January 27, 2005 Shen et al.
20050027307 February 3, 2005 Schwartz et al.
20050043814 February 24, 2005 Kusanagi et al.
20050064042 March 24, 2005 Vunjak-Novakovia et al.
20050074476 April 7, 2005 Gendler et al.
20050074481 April 7, 2005 Brekke et al.
20050089544 April 28, 2005 Khouri et al.
20050101957 May 12, 2005 Buskirk et al.
20050112761 May 26, 2005 Halvorsen et al.
20050129668 June 16, 2005 Giannetti et al.
20050152882 July 14, 2005 Kizer et al.
20050159820 July 21, 2005 Yoshikawa et al.
20050159822 July 21, 2005 Griffey et al.
20050196460 September 8, 2005 Malinin
20050209705 September 22, 2005 Niederauer et al.
20050222687 October 6, 2005 Vunjak-Novakovia et al.
20050228498 October 13, 2005 Andres
20050240281 October 27, 2005 Slivka et al.
20050251268 November 10, 2005 Truncale
20050260612 November 24, 2005 Padmini et al.
20050261681 November 24, 2005 Branch et al.
20050261767 November 24, 2005 Anderson et al.
20050288796 December 29, 2005 Awad et al.
20060030948 February 9, 2006 Manrique et al.
20060060209 March 23, 2006 Shepard
20060099234 May 11, 2006 Winkler
20060111778 May 25, 2006 Michalow
20060167483 July 27, 2006 Asculai et al.
20060178748 August 10, 2006 Dinger, III et al.
20060200166 September 7, 2006 Hanson et al.
20060210643 September 21, 2006 Truncale et al.
20060216323 September 28, 2006 Knaack et al.
20060216822 September 28, 2006 Mizuno et al.
20060235534 October 19, 2006 Gertzman et al.
20060247790 November 2, 2006 McKay
20060247791 November 2, 2006 McKay et al.
20060251631 November 9, 2006 Adkisson, IV et al.
20060276907 December 7, 2006 Boyer, II et al.
20070009610 January 11, 2007 Syring
20070014867 January 18, 2007 Kusanagi et al.
20070026030 February 1, 2007 Gill et al.
20070036834 February 15, 2007 Pauletti et al.
20070041950 February 22, 2007 Leatherbury et al.
20070055377 March 8, 2007 Hanson et al.
20070065943 March 22, 2007 Smith et al.
20070067032 March 22, 2007 Felt et al.
20070083266 April 12, 2007 Lang
20070093896 April 26, 2007 Malinin
20070093912 April 26, 2007 Borden
20070098759 May 3, 2007 Malinin
20070100045 May 3, 2007 Hodorek
20070113951 May 24, 2007 Huang
20070128155 June 7, 2007 Seyedin
20070134291 June 14, 2007 Ting
20070135917 June 14, 2007 Malinin
20070135918 June 14, 2007 Malinin
20070135928 June 14, 2007 Malinin
20070148242 June 28, 2007 Vilei et al.
20070162121 July 12, 2007 Tarrant et al.
20070168030 July 19, 2007 Edwards et al.
20070172506 July 26, 2007 Nycz et al.
20070179601 August 2, 2007 Hodorek et al.
20070185585 August 9, 2007 Bracy et al.
20070276506 November 29, 2007 Troxel
20070299517 December 27, 2007 Davisson et al.
20070299519 December 27, 2007 Schmieding
20080015709 January 17, 2008 Evans et al.
20080027546 January 31, 2008 Semler et al.
20080031915 February 7, 2008 Becerra Ratia et al.
20080038314 February 14, 2008 Hunziker
20080039939 February 14, 2008 Iwamoto et al.
20080039954 February 14, 2008 Long et al.
20080039955 February 14, 2008 Hunziker
20080051889 February 28, 2008 Hodorek
20080065210 March 13, 2008 McKay
20080077251 March 27, 2008 Chen et al.
20080119947 May 22, 2008 Huckle et al.
20080125863 May 29, 2008 McKay
20080125868 May 29, 2008 Branemark
20080138414 June 12, 2008 Hunckle et al.
20080153157 June 26, 2008 Yao et al.
20080154372 June 26, 2008 Peckham
20080167716 July 10, 2008 Schwartz et al.
20080183300 July 31, 2008 Seedhom et al.
20080305145 December 11, 2008 Shelby et al.
20090043389 February 12, 2009 Vunjak-Novakovic et al.
20090069901 March 12, 2009 Truncale et al.
20090069904 March 12, 2009 Picha
20090076624 March 19, 2009 Rahaman et al.
20090081276 March 26, 2009 Alsberg et al.
20090099661 April 16, 2009 Bhattacharya et al.
20090117652 May 7, 2009 Luyten et al.
20090131986 May 21, 2009 Lee et al.
20090149893 June 11, 2009 Semler et al.
20090210057 August 20, 2009 Liao et al.
20090226523 September 10, 2009 Behnam et al.
20090280179 November 12, 2009 Neumann et al.
20090299475 December 3, 2009 Yamamoto et al.
20090312805 December 17, 2009 Lang et al.
20090312842 December 17, 2009 Bursac et al.
20090319051 December 24, 2009 Nycz et al.
20100021521 January 28, 2010 Xu et al.
20100036492 February 11, 2010 Hung et al.
20100036503 February 11, 2010 Chen et al.
Foreign Patent Documents
0517030 December 1992 EP
0522569 January 1993 EP
0762903 June 1995 EP
0762903 December 1995 EP
0517030 September 1996 EP
0739631 October 1996 EP
0784985 July 1997 EP
0968012 September 1998 EP
1719531 May 2001 EP
1237511 June 2001 EP
1237511 June 2001 EP
1127581 August 2001 EP
1181908 February 2002 EP
1234552 August 2002 EP
1234555 August 2002 EP
0739631 March 2003 EP
1181908 December 2003 EP
1384452 January 2004 EP
1234555 June 2004 EP
1618178 November 2004 EP
1127581 June 2005 EP
1561481 August 2005 EP
1618178 January 2006 EP
1234552 August 2006 EP
0968012 September 2006 EP
1719463 November 2006 EP
1719532 November 2006 EP
1234555 February 2007 EP
0762903 August 2007 EP
1537883 April 2008 EP
2102811 February 1983 GB
1454423 January 1989 SU
WO 84/04880 December 1984 WO
90/01342 February 1990 WO
93/16739 September 1993 WO
WO 94/03584 February 1994 WO
95/25748 September 1995 WO
WO 95/33502 December 1995 WO
95/24310 August 1996 WO
WO 98/14222 April 1998 WO
WO 98/41246 September 1998 WO
98/43686 October 1998 WO
WO 99/09914 March 1999 WO
WO 99/11298 March 1999 WO
99/15209 April 1999 WO
WO 99/21497 May 1999 WO
WO 99/22747 May 1999 WO
WO 99/48541 September 1999 WO
WO 99/52572 October 1999 WO
99/56797 November 1999 WO
WO 00/40177 July 2000 WO
00/47114 August 2000 WO
01/07595 February 2001 WO
01/38357 May 2001 WO
01/39788 June 2001 WO
01/46416 June 2001 WO
WO 01/043667 June 2001 WO
02/18546 March 2002 WO
02/22779 March 2002 WO
02/95019 March 2002 WO
02/36732 May 2002 WO
WO 02/058484 August 2002 WO
WO 02/064180 August 2002 WO
02/077199 October 2002 WO
02/095019 November 2002 WO
WO 03/007805 January 2003 WO
WO 03/007805 January 2003 WO
03/007873 January 2003 WO
WO 03/007879 January 2003 WO
WO 03/007879 January 2003 WO
03/012053 February 2003 WO
03/079985 October 2003 WO
03/087160 October 2003 WO
03/094835 November 2003 WO
2004/067704 August 2004 WO
2004/069298 August 2004 WO
WO 2004/075940 September 2004 WO
WO 2004/096983 November 2004 WO
WO 2004/096983 November 2004 WO
WO 2004/103224 December 2004 WO
2005058207 June 2005 WO
WO 2005/110278 November 2005 WO
WO 2005/110278 November 2005 WO
WO 2006/042311 April 2006 WO
WO 2006/042311 April 2006 WO
2006/050213 May 2006 WO
02/36732 September 2006 WO
2006/113586 October 2006 WO
03/094835 December 2006 WO
WO 2007/024238 March 2007 WO
2006/113586 September 2007 WO
2008/013763 January 2008 WO
WO 2008/021127 February 2008 WO
2008/038287 April 2008 WO
2008/013763 June 2008 WO
2008/081463 July 2008 WO
2008/038287 September 2008 WO
WO 2008/106254 September 2008 WO
WO 2009/076164 June 2009 WO
WO 2009/111069 September 2009 WO
Other references
  • (No Author)“Lyophilization” TechnoBusinesss-Solutions. (No publication date). Retrieved Jul. 1, 2009 from URL: <http://www.technobusiness-solutions.com/article-lyophilization1.html> 10 pages.
  • Hunziker, “Articular Cartilage Repair: Basic Science and Clinical Progress. A Review of the Current Status and Prospects”, Osteoarthritis and Cartilage 2001, vol. 10, No. 6, pp. 432-463.
  • Chen et al., “Repair of Articular Cartilage Defects: Part I. Basic Science of Cartilage Healing”, The American Journal of Orthopedics, Jan. 1999, pp. 31-33.
  • Chen et al., “Repair of Articular Cartilage Defects: Part II. Treatment Options”, The American Journal of Orthopedics, Feb. 1999, pp. 88-96.
  • Buckwalter, “Articular Cartilage Injuries”, Clinical Orthopaedics and Related Research, 2002, No. 402, pp. 21-37.
  • Nixon et al., “New Horizons in Articular Cartilage Repair”, Proceedings of the Annual Convention of the AAEP, 2001, vol. 47, pp. 217-226.
  • Tsumaki et al., “Role of CDMP-1 in Skeletal Morphogenesis: Promotion of Mesenchymal Cell Recruitment and Chondrocyte Differentiation”, J. Cell Biol., Jan. 1999, vol. 144, No. 1, 161-173.
  • Feczko et al., “Experimental Results of Donor Site Filling for Autologous Osteochondral Mosaicplasty”, Arthroscopy: The Journal of Arthroscopic and Related Surgery, vol. 19, No. 7 (Sep. 2003), pp. 755-761.
  • Peretti et al., “Cell-Based Bonding of Articular Cartilage: An Extended Study”, Journal of Biomedical Materials Research, 64A, 2003, pp. 517-524.
  • Peretti et al., “Cell-Based Tissue-Engineered Allogeneic Implant for Cartilage Repair”, Tissue Engineering, 2000, vol. 6, No. 5, pp. 567-576.
  • Bugbee, “Fresh Osteochondral Allografting”, Operative Techniques in Sports Medicine, Apr. 2000, vol. 8, No. 2, pp. 158-162.
  • Jackson et al., “Cartilage Substitutes: Overview of Basic Science & Treatment Options”, Journal of American Academy of Orthopaedic Surgeons, vol. 9, Jan./Feb. 2001, pp. 37-52.
  • Verbruggen et al., “Repair Function in Organ Cultured Human Cartilage. Replacement of Enzymatically Removed Proteoglycans During Longterm Organ Culture”, The Journal of Rheumatology, 12:4, 1985, pp. 665-674.
  • Glowacki, “Engineered Cartilage, Bone, Joints and Menisci—Potential for Temporomandibular Joint Reconstruction”, Cells Tissues Organs, vol. 169, Issue 3, 2001, pp. 302-308.
  • Peretti et al., “A Biomechanical Analysis of an Engineered Cell-Scaffold Implant for Cartilage Repair”, Annals of Plastic Surgery, 2001, vol. 46, No. 5, pp. 533-537.
  • Peretti et al., “A Biomechanical Analysis of a Chondrocyte-Based Repair Model of Articular Cartilage”, Tissue Engineering, Aug. 1, 1999, vol. 5, No. 4, pp. 317-326.
  • Peretti et al., “In Vitro Bonding of Pre-seeded Chondrocytes”, Sport Sciences for Health, May 1, 2007, vol. 2, No. 1, pp. 29-33.
  • Peretti et al., “Bonding of Cartilage Matrices with Cultured Chondrocytes: An Experimental Model”, Journal of Orthopedic Research, Jan. 1998, vol. 16, No. 1, pp. 89-95.
  • Nettles et al., “In Situ Crosslinkable Hyaluronan For Articular Cartilage Repair”, 50th Annual Meeting of the Orthopaedic Research Society, (Mar. 2004) Paper No. 0202.
  • Nettles et al., “Photocrosslinkable Hyaluronan As a Scaffold for Articular Cartilage Repair”, Annals of Biomedical Engineering, vol. 32, No. 3, Mar. 2004, pp. 391-397.
  • Girotto et al., “Tissue-specific gene expression in chondrocytes grown on three-dimensional hyaluronic acid scaffolds”, Biomaterials, vol. 24 (2003), pp. 3265-3275.
  • Gertzman et al., “A pilot study evaluating sodium hyaluronate as a carrier for freeze-dried demineralized bone powder”, Cell and Tissue Banking, vol. 2, 2001, pp. 87-94.
  • Trzeciak et al., “Evaluation of Cartilage Reconstruction by Means of Autologous Chondrocyte Versus Periosteal Graft Transplantation: An Animal Study”, Transplantation Proceedings, vol. 38 (2006), pp. 305-311.
  • Brighton et al., “Articular Cartilage Preservation and Storage—I. Application of Tissue Culture Techniques to the Storage of Viable Articular Cartilage”, Arthritis and Rheumatism, vol. 22, No. 10 (Oct. 1979) pp. 1093-1101.
  • Mahadev et al., “Autogenous Osteochondral Morselised Grafts for Full Thickness Osteochondral Defects in the Knee Joints of Pigs”, Singapore Medical Journal, 2001, vol. 42(9), pp. 410-416.
  • Hunziker, “Articular Cartilage Structure in Humans and Experimental Animals”, Articular Cartilage and Osteoarthritis, Raven Press, ed., 1992, pp. 183-199.
  • Diduch et al., “Joint Repair: Treatment Options for Articular Cartilage Injury” Orthopedic Technology Review (2002) 4:24-27.
  • Stone, et al., “One-step American Technique of Articular Cartilage Paste Grafting to Traumatic and Arthritic Defects in the Knee Joint (2-7 Years Follow Up)”, downloaded from http://www.stoneclinic.com/onestep.htm, publication date unavailable. Downloaded Apr. 4, 2008.
  • Gilbert, et al., “Decellularization of Tissue and Organs”, Biomaterials (2006) 27:3675-3683.
  • Non-final Office Action mailed on Feb. 6, 2007 in connection with U.S. Appl. No. 10/438,883.
  • Non-final Office Action mailed on Nov. 5, 2004 in connection with U.S. Appl. No. 10/438,883.
  • Office Action issued on Apr. 24, 2007 in connection with Australian Patent Application No. 2004235291.
  • Non-final Office Action mailed on May 3, 2005 in connection with U.S. Appl. No. 10/438,883.
  • Final Office Action mailed on Oct. 18, 2005 in connection with U.S. Appl. No. 10/438,883.
  • USPTO Communication mailed Oct. 9, 2007 in connection with U.S. Appl. No. 10/438,883.
  • Non-final Office Action mailed on Apr. 19, 2007 in connection with U.S. Appl. No. 11/151,270.
  • Final Office Action mailed on Oct. 9, 2007 in connection with U.S. Appl. No. 11/151,270.
  • Advisory Action mailed on Dec. 27, 2007 in connection with U.S. Appl. No. 11/151,270.
  • Office Action mailed Feb. 7, 2008 in connection with U.S. Appl. No. 10/815,778.
  • Non-final Office Action mailed on Feb. 20, 2007 in connection with U.S. Appl. No. 10/960,960.
  • Final Office Action mailed on Sep. 28, 2007 in connection with U.S. Appl. No. 10/960,960.
  • Non-final Office Action mailed on Dec. 18, 2007 in connection with U.S. Appl. No. 11/081,103.
  • Office Action issued on Nov. 7, 2007 in connection with New Zealand Patent Application No. 543665.
  • U.S. Appl. No. 12/010,984, filed Jan. 31, 2008 titled Cartilage Repair Mixture Containing Allograft Chondroctypes.
  • U.S. Appl. No. 11/657,042, filed Jan. 24, 2007 titled Two Piece Cancellous Construct for Cartilage Repair.
  • U.S. Appl. No. 12/043,001, filed Mar. 5, 2008 Cancellous Construct with Support Ring for Repair of Osteochondral Defects.
  • U.S. Appl. No. 12/079,629, filed Mar. 26, 2008 Titled Cartilage Implant Plug with Fibrin Glue and Method for Implantation.
  • International Search Report issued in connection with International Patent Application No. PCT/US2004/010957 Application on Nov. 1, 2004.
  • International Preliminary Report on Patentability issued on Nov. 18, 2005 in connection with International Patent Application No. PCT/US2004/010957.
  • International Search Report issued in connection with International Patent Application No. PCT/US2005/030610 on Apr. 7, 2006.
  • Written Opinion issued on Apr. 7, 2006 in connection with International Patent Application No. PCT/US2005/030610.
  • International Search Report issued on Sep. 21, 2006 in connection with International Patent Application No. PCT/US2005/036878.
  • International Preliminary Report on Patentability issued on Apr. 17, 2007 2006 in connection with International Patent Application No. PCT/US2005/036878.
  • Office Action issued on Sep. 8, 2006 in connection with European Patent Application No. 04749924.9.
  • Supplementary European Search Report issued on Jun. 28, 2006 in connection with European Patent Application No. 04749924.9.
  • International Search Report issued in connection with International Patent Application No. PCT/US2005/008798 on Jun. 19, 2006.
  • Written Opinion issued in connection with International Patent Application No. PCT/US2005/008798 on Jun. 19, 2006.
  • International Preliminary Report on Patentability issued in connection with International Patent Application No. PCT/US2005/008798 on Nov. 1, 2006.
  • International Search Report issued in connection with International Patent Application No. PCT/US2004/010956 on Oct. 28, 2005.
  • Written Opinion issued in connection with International Patent Application No. PCT/US2004/010956 on Oct. 28, 2005.
  • International Preliminary Report on Patentability issued on Nov. 18, 2005 in connection with International Patent Application No. PCT/US2004/010956.
  • International Patent Application No. PCT/US2008/051796 filed Jan. 23, 2008 titled Two Piece Cancellous Construct for Cartilage Repair.
  • Written Opinion issued in connection with International Patent Application No. PCT/US2004/010957 on Nov. 1, 2004.
  • International Preliminary Report on Patentability issued on Feb. 26, 2008 in connection with International Patent Application No. PCT/US2005/030610.
  • Written Opinion issued in connection with International Patent Application No. PCT/US2005/036878 on Sep. 21, 2006.
  • Hoffman, “Hydrogels for Biomedical Applications”, Advanced Drug Delivery Reviews, 2002, vol. 43, pp. 3-12.
  • Dahlberg et al., “Demineralized Allogeneic Bone Matrix for Cartilage Repair”, Journal of Orthopaedic Research, 1991, vol. 9, pp. 11-19.
  • Lu et al., “Minced Cartilage without Cell Culture Serves as an Effective Intraoperative Cell Source for Cartilage Repair”, Journal of Orthopaedic Research, Jun. 2006, vol. 24, pp. 1261-1270.
  • Stone et al., “Articular Cartilage Paste Grafting to Full-Thickness Articular Cartilage Knee Joint Lesions: A 2- to 12-Year Follow-up”, Arthroscopy: The Journal of Arthoscopic and Related Surgery, Mar. 2006, vol. 22, No. 3, pp. 291-299.
  • Newman, “Articular Cartilage Repair”, American Journal of Sports Medicine, 1998, vol. 26, No. 2, pp. 309-324.
  • Brittberg et al., “Treatment of Deep Cartilage Defects in the Knee with Autologous Chondrocyte Transplantation”, New England Journal of Medicine, Oct. 6, 1994, vol. 331, No. 14, pp. 889-895.
  • Nixon et al., “Enhanced Repair of Extensive Articular Defects by Insulin-like Growth Factor-I-Laden Fibrin Composites”, Journal of Orthopaedic Research, 1999; 17:475-487.
  • International Cartilage Repair Society, “Cartilage Injury Evaluation Package”, www.cartilage.org, 2000.
  • Richardson et al., “Repair of Human Articular Cartilage After Implantation of Autologous Chondrocytes”, Journal of Bone and Joint Surgery [Br], 1999, 81-B:1064-1068.
  • Brittberg et al., “Autologous Chondrocytes Used for Articular Cartilage Repair: An Update”, Clinical Orthopaedics and Related Research, 2001; No. 391 Suppl: S337-S348.
  • Peterson et al., “Two- to 9-year Outcome After Autologous Chondrocyte Transplantation of the Knee”, Clinical Orthopaedic and Related Research, 2000; No. 374: 212-234.
  • Peterson et al., “Autologous Chondrocyte Transplantation: Biomechanics and Long-term Durability”, American Journal of Sports Medicine, 2002, vol. 30, No. 1, pp. 2-12.
  • Messner et al., “Cartilage Repair: A Critical Review”, Acta Orthopaedic Scandinavica, 1996, vol. 67, No. 5, pp. 523-529.
  • Messner et al., “The Long-term Prognosis for Severe Damage to Weight-bearing Cartilage in the Knee: A 14-year Clinical and Radiographic Follow-up in 28 Young Athletes”, Acta Orthopaedic Scandinavica, 1996, vol. 67, No. 2, pp. 165-168.
  • Buckwalter et al., “Articular Cartilage: Degeneration and Osteoarthritis, Repair, Regeneration, and Transplantation”, AAOS Instructional Course Lectures, 1998; 47:487-504.
  • Breinan et al., “Effect of Cultured Autologous Chondrocytes on Repair of Chondral Defects in a Canine Model”, Journal of Bone and Joint Surgery [Am], Oct. 1997; vol. 79-A, No. 10, 1439-1451.
  • Breinan et al., “Autologous Chondrocyte Implantation in a Canine Model: Change in Composition of Reparative Tissue with Time”, Journal of Orthopaedic Research, 2001; 19:482-492.
  • Brittberg et al., “Rabbit Articular Cartilage Defects Treated with Autologous Cultured Chondrocytes”, Clinical Orthopaedics and Related Research, 1996; 326:270-283.
  • Nehrer et al., “Chondrocyte-seeded Collagen Matrices Implanted in a Chondral Defect in a Canine Model”, Biomaterials, 1998; 19:2313-2328.
  • Vunjak-Novakovic et al., “Bioreactor Cultivation Conditions Modulate the Composition and Mechanical Properties of Tissue-Engineered Cartilage”, Journal of Orthopaedic Research, 1999; 17:130-138.
  • Bursac, “Collagen Network Contributions to Structure-Function Relationships in Cartilaginous Tissues in Compression” (Dissertation), Boston University College of Engineering, 2002.
  • Gooch et al., “IGF-I and Mechanical Environment Interact to Modulate Engineered Cartilage Development”, Biochemical and Biophysical Research Communications, 2001; 286:909-915.
  • Pei et al., “Growth Factors for Sequential Cellular De- and Re-differentiation in Tissue Engineering”, Biochemical and Biophysical Research Comunications, 2002; 294:149-154.
  • Obradovic et al., “Integration of Engineered Cartilage”, Journal of Orthopaedic Research, 19:1089-1097, 2001.
  • Schaefer et al., “Tissue Engineered Composites for tha Repair of Large Osteochondral Defects”, Arthritis & Rheumatism, 46(9): 2524-2534 (2002).
  • Pei et al., “Bioreactors Mediate the Effectiveness of Tissue Engineering Scaffolds”, The FASEB Journal, 16:1691-1694, published online (Aug. 7, 2002), 10.1096/fj.02-0083fje.
  • Madry et al., “Gene Transfer of a Human Insulin-like Growth Factor I cDNA Enhances Tissue Engineering of Cartilage”, Human Gene Therapy, 13: 1621-1630 (Sep. 1, 2002).
  • Pearson et al. (eds.), American Association of Tissue Banks, Standards for Tissue Banking, 2008 (12th ed.), pp. 53-56, 86-88.
  • Ornits et al., “Protein Family Review: Fibroblast Growth Factors”, Genome Biology (2001) 2(3): reviews 3005.1-3005.12, http://genomebiology.com/2001/2/3/reviews/3005.1.
  • Loeser et al., “Basic Fibroblast Growth Factor Inhibits the Anabolic of Insulin-like Growth Factor 1 and Osteogenic Protein 1 in Adult Human Articular Chondrocytes”, Arthritis & Rheumatism, vol. 52, No. 12 (Dec. 2005), pp. 3910-3917.
  • Kato et al., “Fibroblast Growth Factor is an Inhibitor of Chondrocyte Terminal Defferentiation”, Journal of Biological Chemistry, vol. 265, No. 10 (Apr. 5, 1990) pp. 5903-5909.
  • Andrés et al., “A Pro-Inflammatory Signature Mediates FGF2-induced Angiogenesis”, Journal of Cellular and Molecular Medicine, (2008).
  • Burger et al., “Fibroblast growth factor receptor-1 is expressed by endothelial progenitor cells”, Blood, vol. 100, No. 10 (Nov. 15, 2002) 3527-35.
  • Baird, “Fibroblast growth factors: activities and significance of non-neurotrophin neurotrophic growth factors”, Current Opinions in Neurobiology, (1994) 4:78-86.
  • Mazué et al., “Preclinical and Clinical Studies with Recombinant Human Basic Fibroblast Growth Factor”, Annals New York Academy of Sciences, (1991) 329-340.
  • Aviles et al., “Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF-2)”, British Journal of Pharmacology (2003) 140: 637-646.
  • Nolan et al., “Living Bone Grafts”, BMJ, vol. 304, Jun. 13, 1992, pp. 1520 and 1521.
  • Osteo Sponge product information, Bacterin International Inc., May 2005.
  • A non-final Office Action mailed on Jun. 8, 2009 in connection with U.S. Appl. No. 11/481,955.
  • A non-final Office Action mailed on Jul. 9, 2008 in connection with U.S. Appl. No. 11/151,270.
  • A final Office Action mailed on Nov. 13, 2008 in connection with U.S. Appl. No. 10/815,778.
  • A non-final Office Action mailed on Jul. 2, 2009 in connection with U.S. Appl. No. 10/815,778.
  • A non-final Office Action mailed on May 18, 2009 in connection with U.S. Appl. No. 11/657,042.
  • U.S. Appl. No. 12/381,072, filed Mar. 5, 2009 entitled “Cancellous Constructs, Cartilage Particles and Combinations of Cancellous Constructs and Cartilage Particles”.
  • A final Office Action mailed on Sep. 19, 2008 in connection with U.S. Appl. No. 11/081,103.
  • U.S. Appl. No. 12/508,892, filed Jul. 24, 2009 entitled “Cancellous Constructs with Support Ring for Repair of Osteochondral Defects”.
  • An International Search Report issued on Jun. 23, 2009 in connection with International Patent Application No. PCT/US2008/051796.
  • A Written Opinion issued on Jun. 23, 2009 in connection with International Patent Application No. PCT/US2008/051796.
  • An International Preliminary Report on Patentability issued on Jul. 28, 2009 in connection with International Patent Application No. PCT/US2008/051796.
  • An International Search Report issued on Jul. 6, 2009 in connection with International Patent Application No. PCT/US2008/085522.
  • A Written Opinion issued on Jul. 6, 2009 in connection with International Patent Application No. PCT/US2008/085522.
  • An International Search Report issued on Jul. 6, 2009 in connection with International Patent Application No. PCT/US2009/001459.
  • A Written Opinion issued on Jul. 6, 2009 in connection with International Patent Application No. PCT/US2009/001459.
  • Canadian Office Action issued on Aug. 24, 2009 in connection with Canadian Patent Application No. 2,563,082.
  • http://www.stoneclinic.com/articularcartilagepastegrafting, no date.
  • http://www.technobusiness-solutions.com/article-lyophilization1.html, published Feb. 12, 2002.
  • Non-final Office Action mailed on Jul. 22, 2009 in connection with U.S. Appl. No. 12/010,984.
  • Non-final Office Action mailed on Jun. 3, 2009 in connection with U.S. Appl. No. 11/081,103.
  • Non-Final Office Action for U.S. Appl. No. 11/081,103, mailed Jan. 14, 2010.
  • Final Office Action for U.S. Appl. No. 11/481,955, mailed Jan. 7, 2010.
  • Crescenzi et al., “Hyaluronan Linear and Crosslinked Derivatives as Potential/Actual Biomaterials”, in Hyaluronan (2002), vol. 1 (Chemical, Biochemical and Biological Aspects), J. F. Kennedy et al., Ed., pp. 261-268.
  • Michielen et al., “Novel Biomaterials Based on Cross-linked Hyaluronan: Structural Investigations”, in Hyaluronan (2002), vol. 1 (Chemical, Biochemical and Biological Aspects), J. F. Kennedy et al., Ed., pp. 269-276.
  • U.S. Appl. No. 12/696,366, filed Jan. 29, 2010.
  • U.S. Appl. No. 12/657,207, filed Jan. 14, 2010.
  • Office Action dated Jan. 14, 2010, received in U.S. Appl. No. 11/081,103, filed on Mar. 16, 2005.
  • Yee, Cindy J. et al., (2000) Analysis of fibroblast growth factor receptor 3 S249C mutation in cervical carcinoma. Journal of the National Cancer Institute 92(22):1848-1849.
  • Zhang, Jiandong et al., (1991) Three-dimensional structure of human basic fibroblast growth factor, a structural homolog of interleukin 1 Beta. Proc Natl Acad Sci. USA 88(8):3446-3450.
  • Zhu, Hengyi et al., (1995) Glu-96 of basic fibroblast growth factor is essential for high affinity receptor binding. Journal Of Biological Chemistry 270(37):21869-21874.
  • Zhu, Hengyi et al., (1997) Analysis of high-affinity binding determinants in the receptor binding epitope of basic fibroblast growth factor. Protein Engineering 10(4):417-421.
  • Carr, M. E. Jr. and Alving, B. M. (1995) Effect of fibrin structure on plasmin-mediated dissolution of plasma clots. Blood Coag, Fibrinol. 6(6):567-573.
  • Carr, Marcus E. (1998) Fibrin formed in plasma is composed of fibers more massive than those formed from purified fibrinogen. Thromb. Haemost. 59(3):535-539.
  • Cook, James L. et al., (2003) Biocompatibility of three-dimensional chondrocyte grafts in large tibial defects of rabbits. Am J Vet Res. 64(1):12-20.
  • Gao, Jizong et al., (2002) Repair of osteochondral defect with tissue-engineered two-phase composite material of injectable calcium phosphate and hyaluronan sponge. Tissue Engin. Part A 8(5):827-837.
  • Gruber, Reinhard et al., (2002) Platelets stimulate proliferation of bone cells: involvement of platelet-derived growth factor, microparticles and membranes. Clin Oral Implants Res. 13(5):529-535.
  • Haisch, A. et al., (2000) Preparation of a pure autologous biodegradable fibrin matrix for tissue engineering. Med Biol Eng Comput. 38(6):686-689.
  • Itokazu, M. et al., (1997) The sustained release of antibiotic from freeze-dried fibrin-antibioticcompound and efficacies in a rat model of osteomyelitis. Infection 25(6):359-363.
  • Sims, C. Derek et al., (1998) Tissue engineered neocartilage using plasma derived polymer substrates and chondrocytes. Plastic & Recon. Surg. 101(6):1580-1585.
  • “Young's Modulus,” Entry on http://en.wikipedia.org. accessed Oct. 27, 2005. 3 pages.
  • Bradford, Marion M. (1976) A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding. Analytical Biochemistry 72(1-2):248-254.
  • Matsuda et al. (1995) In Vivo Chondrogenesis in Collagen Sponge Sandwiched by Perichondrium. J. Biomater. Sci. Polymer Ed., vol. 7, No. 3, pp. 221-229.
  • Fujisato et al., (1996) Effect of basic fibroblast growth factor on cartilage regeneration in chondrocyte-seeded collagen sponge scaffold. Biomaterials, vol. 17, No. 2, pp. 155-162.
  • Non-Final Office Action mailed Apr. 15, 2010 in connection with U.S. Appl. No. 12/079,629.
  • Non-Final Office Action mailed Apr. 12, 2010 in connection with U.S. Appl. No. 12/191,490.
  • Non-Final Office Action mailed Apr. 15, 2010 in connection with U.S. Appl. No. 11/657,042.
  • International Preliminary Report on Patentability for PCT/US2009/001459, mailed on May 12, 2010.
  • Atala et al., Injectable alginate seeded with chondrocytes as a potential treatment for vesicoureteral reflux, J. of Urology 150(2 Pt 2):745-7 (1993).
  • International Preliminary Report on Patentability for PCT/US2008/085522, mailed on Jun. 17, 2010.
  • Nettles et al. (Mar. 2004), “In Situ Crosslinkable Hyaluronan For Articular Cartilage Repair”, 50th Annual Meeting of the Orthopaedic Research Society, Paper No. 0202.
  • Final Office Action for U.S. Appl. No. 11/081,103, mailed Aug. 11, 2010.
  • Non-final Office Action for U.S. Appl. No. 12/010,984, mailed Aug. 16, 2010.
  • Abraham, Judith A. et al., (1986) Human Basic Fibroblast Growth Factor: Nucleotide Sequence And Genomic Organization. EMBO Journal 5(10):2523-2528.
  • Agrawal, Sudhir et al., (1991) Pharmacokinetics. Biodistribution, And Stability Of Oligodeoxynucleotide Phosphorothioates In Mice. Proc Natl Acad Sci. USA 88(17):7595-7599.
  • Arakawa, Tsutomu et al., (1993) Production and Characterization of an Analog of Acidic Fibroblast Growth Factor With Enhanced Stability and Biological Activity. Protein Engineering 6(5):541-546.
  • Bailly, Karine et al., (2000) Uncoupling of cell proliferation and differentiation activities of basic fibroblast growth factor. FASEB Journal 14(2):333-343.
  • Bange, Johannes et al., (2002) Cancer progression and tumor cell motility are associated with the FGFR4 Arg388 Allele. Cancer Research 62(3):840-846.
  • Bork, Peer (2000) Powers and pitfalls in sequence analysis: The 70% hurdle. Genome Res. 10(4):398-400.
  • Bork, Peer and Bairoch, Amnon (1996) Go hunting in sequence databases but watch out for the traps. Trends in Genetics 12(10):425-427.
  • Brenner, Steven E. (1999) Errors in genome annotation. Trends in Genetics 15(4):132-133.
  • Cappellen, David et al., (1999) Frequent activating mutations of FGFR3 In human bladder arid cervix carcinomas. Nature Genetics 23(1):18-20.
  • Chusho, Hideki et al., (2001) Dwarfism and earlydeath in mice lacking C-type Natriuretic Peptide. Proc Natl Acad Sci. 98(7):4016-4021.
  • Coughlin, Shaun R. et al., (1988) Acidic and basic fibroblast growth factors stimulate tyrosine kinase activity in vivo. J Biol Chem. 263(2):988-993.
  • Dell'Accio, Francesco et al., (2001) Molecular markers predictive of the capacity of expanded human articular chondrocytes to form stable cartilage in vivo, Arthritis Rheum. 44(7):1608-19.
  • Doerks, Tobias et al., (1998) Protein annotation: detective work for function prediction. Trends Genet. 14(6):248-250.
  • Dvorakova, Dana et al., (2001) Changes in the expression of FGFR3 in patients with chronic myeloid leukaemia receiving transplant of allogeneic peripheral blood stem cells_British Journal Haematology 13(3):832-835.
  • Eriksson, A. Elisabeth et al., (1991) Three-dimensional structure of human basic fibroblast growth factor. Proc. Natl. Acad. Sci. USA 88:3441-3445 (XP002936511).
  • Ezzat Shereen et al., (2002) Targeted expression of A Human pituitary tumor-derived isoform of FGF Receptor-4 Recapitulates Pituitary Tumorigenesis. Journal of Clinical Investigation 109(1):69-77.
  • Faham, Salem et al., (1998) Diversity does make a difference: fibroblast growth factor—Heparin Interactions. Curr Opin Struct Biol 8(5):578-586.
  • Fingl, Edward and Woodbury, Dixon M.(1975) Chapter I: General Priciples; In: The Pharmacological Basis of Therapeutics. Fifth edition. Goodman, Louis S. and Gilman, Alfred editors. 1:1-45.
  • Gargiulo, B. J. et al., (2002) Phenotypic modulation of human articular chondrocytes by bistratene A. Eur Cell Mater. 3:9-18.
  • Givol, David and Yayon, Avner (1992) Complexity of FGF receptors: genetic basis for structural diversity and functional specificity FASEB J. 6(15):3362-3369.
  • Hecht, H. J. et al., (2000) Structure of fibroblast growth factor 9 shows a symmetric dimer with unique receptor-and heparin-binding interfaces. Acta Cryst. D57:378-384.
  • Johnson, Daniel E. and Williams, Lewis T. (1993) Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res. 60:1-41.
  • Kirikoshi, Hiroyuki et al., (2000) Molecular cloning and characterization of Human FGF-20 on chromosome 8p21.3-p22. Biochem Biophys Res Commun. 274(2):337-343.
  • Kuroda, S. et al., (1999) Anabolic effect of aminoterminally truncated Fibroblast Growth Factor 4 (FGF4) on bone. Bone 25:(4):431-437.
  • Nakatake, Yuhki et al., (2001) Identification of a novel fibroblast growth factor. FGF-22, preferentially expressed in the inner root sheath of the hair follicle. Biochim Biophys Acta. 1517(3):460-463.
  • Ngo, J. Thomas et al., (1994) Computational complexity, protein structure prediction, and the Levithal Paradox. In: The Protein Folding Problem and Tertiary Structure Prediction. K. Merz Jr. and S. Le Grand, Editors. 433-506.
  • Nishimura, Tetsuya et al., (2000) Identification Of a Novel FGF, FGF-21, Preferentially Expressed In The Liver. Biochim Biophys Acta 1492(1):203-206.
  • Okada-Ban, Mai et al., (2000) Fibroblast growth factor-2. International Journal of Biochemistry & Cell Biology 32 (3):263-267.
  • Olsen, Shaun K. (2003) Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs J. Biol Chem. 278(36); pp. 34226-34236.
  • Ornitz, David M. et al., (1996) Receptor specificity of the fibroblast growth factor family. J Biol Chem. 271(25)15292-7.
  • Ornitz, David M. (2000) FGFs, heparan sulfate and FGFRs: Complex interactions essential for development. Bio Essays 22:108-112.
  • Pellegrini, Luca et al., (2000) Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature 407(6807):1029-1034.
  • Pillai, Omathanu and Panchagnula, Ramesh (2001) Polymers in drug delivery. Curr Opin Chem Biol 5 (4):447-451.
  • Plotnikov, Alexander N. et al., (1999) Structural basis for FGF receptor dimerization and activation. Cell 98 (5):641-650.
  • Plotnikov, Alexander N. et al., (2000) Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity. Cell 101(4):413-424.
  • Sahni, Malika et al., (1999) FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev. 13:1361-1366.
  • Schlessinger, Joseph et al., (2000) Crystal structure of a ternary FGF-FGFR-1 Heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell 6(3):743-750.
  • Schmal, H. et al., (2007) bFGF influences human articular chondrocytes differentiation. Cytotherapy 9(2):184-93.
  • Seno, Masaharu et al., (1990) Carboxyl-terminal structure of basic fibroblast growth factor significantly contributes to its affinity for Heparin. Eur J Biochem. 188:239-245.
  • Shano; Zhang-Qiang et al., (2006) Effects of intramyocardial administration of slow-release basic fibroblast growth factor on angiogenesis and ventricular remodelling in a rat infarct model. Circ. J. 70(4):471-477.
  • Skolnik, Jeffrey and Fetrow, Jacquelyn S. (2000) From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends Bio Technol. 18(1):34-39.
  • Sleeman, Matthew et al., (2001) Identification of a new fibroblast growth factor receptor, FGFR5. Gene 271 (2):171-182.
  • Smith, Temple and Zhang, Xiaolin (1997) The challenges of genome sequence annotation or The devil is in the details, Nat Biotecehnol. 15(12):1222-1223.
  • Springer, Barry A. et al., (1994) Identification and Concerted Function of Two Receptors Binding Surfaces on Basic Fibroblast Growth Factor Required for Mitogenesis. The Journal of Biological Chemistry 269(43):26879-26884.
  • Stauber, Deborah J. et al., (2000) Structural interactions of fibroblast growth factor receptor with its ligands. Proc Natl Acad Sci USA 97(1):49-54.
  • Vajo, Zoltan et al., (2000) The Molecular and Genetic Basis of Fibroblast Growth Factor Receptor 3 Disorders: The Achondroplasia Family of Skeletal Dysplasias, Muenke Craniosynostosis, and Crouzon Syndrome with Acanthosis Nigricans. Endocrine Rev. 21(1):23-39.
  • Wells, James A. (1990) Additivity of mutational effects in proteins. Biochemistry 29(37):8509-8517.
  • Yamashita, Tetsuo et al., (2000) Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochemical and Biophysical Research Communications 277 (2):494-498.
  • Yayon, Avner et al., (1991) Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64(4):841-848.
  • International Search Report and Written Opinion for PCT/US2010/000108, mailed Aug. 24, 2010.
  • International Patent Application No. PCT/US2009/000108, filed Jan. 14, 2010, entitled “Cartilage Particle Tissue Mixtures Optionally Combined With a Cancellous Construct”.
  • Final Office Action mailed Mar. 15, 2010 in connection with U.S. Appl. No. 10/815,778.
  • Final Office Action mailed Mar. 22, 2010 in connection with U.S. Appl. No. 12/010,984.
  • U.S. App. No. 12/881,988, filed Sep. 14, 2010.
  • U.S. Appl. No. 12/924,132, filed Sep. 21, 2010.
  • Temenoff et al., “Review: Tissue engineering for regeneration of articular cartilage”, Biomaterials 21 (2000) pp. 431-440.
  • Hunziker, “Articular cartilage repair: are the intrinsic biological constraints undermining this processiInsuperable?”, Osteoarthritis and Cartilage 7 (1999) pp. 15-28.
Patent History
Patent number: RE42208
Type: Grant
Filed: Jun 26, 2008
Date of Patent: Mar 8, 2011
Assignee: Musculoskeletal Transplant Foundation (Edison, NJ)
Inventors: Katherine Gomes Truncale (Hillsborough, NJ), Arthur A. Gertzman (Flemington, NJ), Moon Hae Sunwoo (Old Tappan, NJ), William W. Tomford (Belmont, MA)
Primary Examiner: Allison M Ford
Attorney: Greenberg Traurig, LLP
Application Number: 12/147,042
Classifications
Current U.S. Class: Animal Or Plant Cell (424/93.7); Derived From Musculoskeletal System, Other Than Cardiac Muscle (e.g., Cartilage, Muscle, Etc.) (424/548)
International Classification: A61K 35/32 (20060101);